AU731137B2 - Transgenic plants expressing assembled secretory antibodies - Google Patents

Transgenic plants expressing assembled secretory antibodies Download PDF

Info

Publication number
AU731137B2
AU731137B2 AU29323/97A AU2932397A AU731137B2 AU 731137 B2 AU731137 B2 AU 731137B2 AU 29323/97 A AU29323/97 A AU 29323/97A AU 2932397 A AU2932397 A AU 2932397A AU 731137 B2 AU731137 B2 AU 731137B2
Authority
AU
Australia
Prior art keywords
plant
immunoglobulin
molecule
chain
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU29323/97A
Other languages
English (en)
Other versions
AU2932397A (en
Inventor
Mich B. Hein
Andrew Hiatt
Julian K.C. Ma
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Institute filed Critical Scripps Research Institute
Publication of AU2932397A publication Critical patent/AU2932397A/en
Application granted granted Critical
Publication of AU731137B2 publication Critical patent/AU731137B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1275—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Streptococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C12N15/8258—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon for the production of oral vaccines (antigens) or immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0002—Antibodies with enzymatic activity, e.g. abzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/13—Immunoglobulins specific features characterized by their source of isolation or production isolated from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU29323/97A 1996-05-03 1997-05-05 Transgenic plants expressing assembled secretory antibodies Ceased AU731137B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/642406 1996-05-03
US08/642,406 US5959177A (en) 1989-10-27 1996-05-03 Transgenic plants expressing assembled secretory antibodies
PCT/US1997/007562 WO1997042313A1 (en) 1996-05-03 1997-05-05 Transgenic plants expressing assembled secretory antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU54001/01A Division AU5400101A (en) 1996-05-03 2001-06-22 Trangenic plants expressing assembled secretory antibodies

Publications (2)

Publication Number Publication Date
AU2932397A AU2932397A (en) 1997-11-26
AU731137B2 true AU731137B2 (en) 2001-03-22

Family

ID=24576415

Family Applications (1)

Application Number Title Priority Date Filing Date
AU29323/97A Ceased AU731137B2 (en) 1996-05-03 1997-05-05 Transgenic plants expressing assembled secretory antibodies

Country Status (6)

Country Link
US (2) US5959177A (enExample)
EP (1) EP0946717A1 (enExample)
JP (1) JP2000510340A (enExample)
AU (1) AU731137B2 (enExample)
CA (1) CA2253454A1 (enExample)
WO (1) WO1997042313A1 (enExample)

Families Citing this family (902)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050241023A1 (en) * 1989-10-27 2005-10-27 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US7037722B1 (en) * 1989-10-27 2006-05-02 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US7005560B1 (en) * 1989-10-27 2006-02-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6995014B1 (en) * 1989-10-27 2006-02-07 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6808709B1 (en) 1994-12-30 2004-10-26 The Regents Of The University Of California Immunoglobulins containing protection proteins and their use
JPH11504901A (ja) 1994-12-30 1999-05-11 プラネット・バイオテクノロジー・インコーポレイテッド 植物における防御タンパク質を含む免疫グロブリンの製造法およびその使用
WO1998057993A1 (en) * 1997-06-19 1998-12-23 The Regents Of The University Of California Secretory immunoglobulin produced by single cells and methods for making and using same
AU3115299A (en) * 1998-03-25 1999-10-18 Planet Biotechnology, Inc. Methods and compositions for production of multimeric proteins in transgenic plants
WO1999054484A1 (en) * 1998-04-20 1999-10-28 The Regents Of The University Of California Modified immunoglobulin molecules and methods for use thereof
US6512162B2 (en) 1998-07-10 2003-01-28 Calgene Llc Expression of eukaryotic peptides in plant plastids
ATE360072T1 (de) * 1998-07-10 2007-05-15 Calgene Llc Expression eukarotischer peptide in pflanzenplastiden
US6998267B1 (en) * 1998-12-09 2006-02-14 The Dow Chemical Company Method for manufacturing glycoproteins having human-type glycosylation
US7485715B2 (en) * 1999-06-18 2009-02-03 Ceres, Inc. Sequence-determined DNA encoding AP2 domain polypeptides
US7479555B2 (en) * 1999-07-21 2009-01-20 Ceres, Inc. Polynucleotides having a nucleotide sequence that encodes a polypeptide having MOV34 family activity
AU1738401A (en) * 1999-10-26 2001-05-08 Plant Research International B.V. Mammalian-type glycosylation in plants
EP1118669A3 (en) * 1999-12-17 2001-08-29 Unilever Plc Production of camelid antibodies in plants
CN101643512A (zh) * 2000-04-28 2010-02-10 行星生物技术有限公司 预防鼻病毒感染的新型免疫粘附素
US20060015969A1 (en) * 2000-04-28 2006-01-19 Planet Biotechnology, Inc. Novel immunoadhesins for treating and prventing toxicity and pathogen-mediated diseases
US7304208B2 (en) * 2000-05-02 2007-12-04 Ventria Bioscience Expression of human serum albumin (HSA) in monocot seeds
US6696620B2 (en) * 2000-05-02 2004-02-24 Epicyte Pharmaceutical, Inc. Immunoglobulin binding protein arrays in eukaryotic cells
US7685052B2 (en) 2000-06-01 2010-03-23 Pipeline Financial Group, Inc. Confidential block trading system and method
US7632983B2 (en) * 2000-07-31 2009-12-15 Biolex Therapeutics, Inc. Expression of monoclonal antibodies in duckweed
BR0113512A (pt) 2000-08-25 2005-05-10 Basf Plant Science Gmbh Polinucleotìdeos de planta que codificam novas prenil proteases
WO2002102855A2 (en) * 2000-11-17 2002-12-27 University Of Rochester In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
US20050196755A1 (en) * 2000-11-17 2005-09-08 Maurice Zauderer In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
US20060064782A1 (en) * 2000-12-18 2006-03-23 Conopco, Inc. Production of antibodies
US7098383B2 (en) * 2000-12-19 2006-08-29 Sembiosys Genetics Inc. Methods for the production of multimeric immunoglobulins, and related compositions
CN100385006C (zh) 2001-01-19 2008-04-30 陶氏化学公司 利用植物细胞分泌性生产具有人型糖链的糖蛋白的方法
AU2002338446A1 (en) * 2001-01-23 2002-11-05 University Of Rochester Medical Center Methods of producing or identifying intrabodies in eukaryotic cells
EP2078455A1 (en) * 2001-03-06 2009-07-15 The Dow Chemical Company Plant cell having animal-type sugar chain adding function
US20050287647A9 (en) 2001-05-30 2005-12-29 Carl Perez Plant artificial chromosomes, uses thereof and methods of preparing plant artificial chromosomes
JP2005525081A (ja) * 2001-06-05 2005-08-25 カレン ケイ． オオイシ 植物からの生物活性ミュラー管抑制物質を含むＴＧＦ−βタンパク質の遺伝子発現および産生法
US20070118934A1 (en) * 2001-10-26 2007-05-24 Planet Biotechnology, Inc. Chimeric toxin receptor proteins and chimeric toxin receptor proteins for treatment and prevention of anthrax
US20030190705A1 (en) 2001-10-29 2003-10-09 Sunol Molecular Corporation Method of humanizing immune system molecules
AR039067A1 (es) * 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US20030166274A1 (en) * 2001-11-15 2003-09-04 Hewitt Charles W. Three-dimensional matrix for producing living tissue equivalents
KR101070518B1 (ko) 2002-03-19 2011-10-05 스티칭 디엔스트 랜드보위쿤디그 온데조에크 식물에서의 ｇｎｔⅲ 발현
WO2003078637A2 (en) * 2002-03-19 2003-09-25 Plant Research International B.V. Optimizing glycan processing in plants
CA2489280A1 (en) * 2002-06-14 2003-12-24 Centocor, Inc. Modified "s" antibodies
AU2003245772A1 (en) 2002-06-28 2004-01-19 University Of Guelph Harvest-inducible genes form alfalfa (medicago sativa) and methods of use thereof
US7329798B2 (en) * 2002-06-28 2008-02-12 University Of Guelph Harvest-inducible regulatory elements and methods of using same
ES2368733T3 (es) 2002-07-18 2011-11-21 Merus B.V. Producción recombinante de mezclas de anticuerpos.
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
US7476777B2 (en) * 2002-09-17 2009-01-13 Ceres, Inc. Biological containment system
MXPA05003003A (es) * 2002-09-17 2005-11-23 Ceres Inc Sistema de contencion biologico.
US20040110930A1 (en) * 2002-10-03 2004-06-10 Reinl Stephen J. Multimeric protein engineering
US6920521B2 (en) * 2002-10-10 2005-07-19 International Business Machines Corporation Method and system of managing virtualized physical memory in a data processing system
WO2004044161A2 (en) * 2002-11-06 2004-05-27 Fraunhofer Usa Expression of foreign sequences in plants using trans-activation system
US7491509B2 (en) 2003-02-03 2009-02-17 Fraunhofer Usa, Inc. System for expression of genes in plants
GB0226878D0 (en) * 2002-11-18 2002-12-24 Univ Warwick Antibodies
AR042145A1 (es) * 2002-11-27 2005-06-08 Dow Agrociences Llc Produccion de inmunoglobulinas en plantas con una fucocilacion reducida
JP4405736B2 (ja) 2003-01-31 2010-01-27 コニカミノルタホールディングス株式会社 データベースシステム
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
WO2004106375A1 (en) 2003-05-30 2004-12-09 Merus Biopharmaceuticals B.V. I.O. Fab library for the preparation of anti vegf and anti rabies virus fabs
US20050138692A1 (en) * 2003-06-02 2005-06-23 Biotechnology Foundation, Inc. Production of cancer-specific antibodies in plants
EP1633876B1 (en) * 2003-06-17 2008-08-20 SemBioSys Genetics Inc. Methods for the production of insulin in plants
HN2004000285A (es) * 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
PL1678314T3 (pl) 2003-10-22 2013-02-28 Keck Graduate Inst Sposoby syntezy polipeptydów heteromultimerycznych w drożdżach, wykorzystujące strategię kojarzenia haploidalnego
TW200526778A (en) * 2003-11-14 2005-08-16 Sembiosys Genetics Inc Methods for the production of apolipoproteins in transgenic plants
JP2007517504A (ja) * 2003-12-09 2007-07-05 ベントリア バイオサイエンス 融合担体として種子貯蔵蛋白を利用する植物種子中の融合ポリペプチドの高水準発現
WO2005077981A2 (en) * 2003-12-22 2005-08-25 Xencor, Inc. Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
CA2551392A1 (en) * 2003-12-23 2005-07-28 Ventria Bioscience Methods of expressing heterologous protein in plant seeds using monocot non seed-storage protein promoters
AR047372A1 (es) * 2004-01-09 2006-01-18 Pfizer Anticuerpos contra madcam
EP1737971B1 (en) 2004-01-20 2017-08-16 Merus N.V. Mixtures of binding proteins
WO2007089610A1 (en) * 2006-01-26 2007-08-09 Ceres, Inc. Modulating plant oil levels
US9758790B2 (en) 2004-12-08 2017-09-12 Ceres, Inc. Modulating the level of components within plants
EP1866418A2 (en) * 2005-02-22 2007-12-19 Ceres Inc. Modulating plant alkaloids
US7312376B2 (en) * 2005-04-20 2007-12-25 Ceres, Inc. Regulatory regions from Papaveraceae
EP1877075A4 (en) * 2005-04-25 2008-07-30 Pfizer ANTIBODY TO MYOSTATIN
MX2007013304A (es) 2005-04-26 2007-12-13 Pfizer Anticuerpos de p-caderina.
WO2006133461A1 (en) * 2005-06-08 2006-12-14 Ceres Inc. Identification of terpenoid-biosynthesis related regulatory protein-regulatory region associations
CN101506238B (zh) * 2005-06-30 2013-11-06 森托科尔公司 具有提高治疗活性的方法和成分
US20070202512A1 (en) * 2005-08-19 2007-08-30 Bristol-Myers Squibb Company Human single nucleotide polymorphisms associated with dose-dependent weight gain and methods of use thereof
PL2447283T3 (pl) 2005-09-07 2015-12-31 Amgen Fremont Inc Ludzkie przeciwciała monoklonalne przeciwko kinazie podobnej do receptora aktywiny-1 (ALK-1)
WO2007041536A2 (en) * 2005-09-30 2007-04-12 Ceres, Inc. Modulating plant tocopherol levels
US20090178160A1 (en) * 2005-10-25 2009-07-09 Joon-Hyun Park Modulation of Triterpenoid Content in Plants
US20090304901A1 (en) * 2006-01-25 2009-12-10 Steven Craig Bobzin Modulating plant protein levels
US20070199090A1 (en) * 2006-02-22 2007-08-23 Nestor Apuya Modulating alkaloid biosynthesis
US20090222957A1 (en) * 2006-04-07 2009-09-03 Ceres Inc. Regulatory protein-regulatory region associations related to alkaloid biosynthesis
WO2007127206A1 (en) 2006-04-26 2007-11-08 Colorado State University Research Foundation Biological systems input-output: response system and plant sentinels
EP2035454A2 (en) * 2006-05-19 2009-03-18 Amgen, Inc. Antibodies to sars coronavirus
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
SI2511301T1 (en) 2006-08-04 2018-05-31 MedImmune Limited, Human antibodies to ERBB 2
KR20090088852A (ko) 2006-09-05 2009-08-20 메다렉스, 인코포레이티드 골형성 단백질의 항체와 이의 수용체 및 이의 사용방법
US8642031B2 (en) 2006-11-02 2014-02-04 Acceleron Pharma, Inc. Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof
US10059756B2 (en) 2006-11-02 2018-08-28 Acceleron Pharma Inc. Compositions comprising ALK1-ECD protein
EP3181580A1 (en) 2006-11-02 2017-06-21 Acceleron Pharma Inc. Alk1 receptor and ligand antagonists and uses thereof
JP2010518115A (ja) 2007-02-09 2010-05-27 ジェネンテック， インコーポレイテッド 抗Ｒｏｂｏ４抗体およびそれらのための使用
KR101426576B1 (ko) 2007-04-17 2014-08-07 스티칭 디엔스트 랜드보위쿤디그 온데조에크 비-포유동물 글리코실트랜스퍼라제의 발현에 의한 식물에서의 포유동물형 글리코실화
CA2993715A1 (en) 2007-05-21 2008-11-27 Alderbio Holdings Llc Antibodies to il-6 and use thereof
ES2687808T3 (es) 2007-09-26 2018-10-29 Chugai Seiyaku Kabushiki Kaisha Región constante de anticuerpo modificado
WO2009070642A1 (en) * 2007-11-28 2009-06-04 Medimmune, Llc Protein formulation
TWI580694B (zh) 2007-11-30 2017-05-01 建南德克公司 抗-ｖｅｇｆ抗體
CN112481367A (zh) * 2008-03-31 2021-03-12 健泰科生物技术公司 用于治疗和诊断哮喘的组合物和方法
KR20190037355A (ko) 2008-05-02 2019-04-05 악셀레론 파마 인코포레이티드 혈관신생 및 혈관주위세포 적용범위의 조정을 위한 ａｌｋ１ 길항제 기재의 방법 및 조성물
NZ590033A (en) 2008-05-30 2011-08-26 Xbiotech Inc Interleukin-1alpha antibodies and methods of use
WO2010065077A2 (en) 2008-11-25 2010-06-10 Alder Biopharmaceuticals, Inc. Antagonists of il-6 to prevent or treat thrombosis
WO2010078376A2 (en) 2008-12-30 2010-07-08 Ventana Medical Systems, Inc. Fc-specific polymer-conjugated antibodies and their diagnostic use
JP5624114B2 (ja) 2009-03-20 2014-11-12 ジェネンテック， インコーポレイテッド 抗ｈｅｒ抗体
SI2417156T1 (sl) 2009-04-07 2015-06-30 Roche Glycart Ag Trivalentna, bispecifiäśna protitelesa
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
CA2772715C (en) 2009-09-02 2019-03-26 Genentech, Inc. Mutant smoothened and methods of using the same
AU2010296018B2 (en) 2009-09-16 2016-05-05 Genentech, Inc. Coiled coil and/or tether containing protein complexes and uses thereof
WO2011071577A1 (en) 2009-12-11 2011-06-16 Genentech, Inc. Anti-vegf-c antibodies and methods using same
CN102770158B (zh) 2009-12-21 2016-10-19 霍夫曼-拉罗奇有限公司 抗体配制剂
ME02288B (me) 2010-02-08 2016-02-20 Regeneron Pharma Miš sa zajedničkim lakim lancem
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
RU2587619C2 (ru) 2010-02-18 2016-06-20 Дженентек, Инк. Антагонисты неурегулина и применение их в лечении злокачественного новообразования
AR080795A1 (es) 2010-03-24 2012-05-09 Genentech Inc Anticuerpos anti-lrp6 (proteina relacionada con el receptor ldl tipo 6)
AR080793A1 (es) 2010-03-26 2012-05-09 Roche Glycart Ag Anticuerpos biespecificos
WO2011147834A1 (en) 2010-05-26 2011-12-01 Roche Glycart Ag Antibodies against cd19 and uses thereof
EP2582729A4 (en) 2010-06-18 2014-05-28 Hoffmann La Roche ANTI-AXL ANTIBODIES AND METHOD FOR THEIR USE
WO2011161119A1 (en) 2010-06-22 2011-12-29 F. Hoffmann-La Roche Ag Antibodies against insulin-like growth factor i receptor and uses thereof
WO2011161189A1 (en) 2010-06-24 2011-12-29 F. Hoffmann-La Roche Ag Anti-hepsin antibodies and methods of use
RU2571226C2 (ru) 2010-07-09 2015-12-20 Дженентек, Инк. Антитела против нейропилина и способы их применения
AR082163A1 (es) 2010-07-15 2012-11-14 Hoffmann La Roche Anticuerpos especificamente ligantes del tslpr humano y metodos de utilizacion de los mismos
WO2012010582A1 (en) 2010-07-21 2012-01-26 Roche Glycart Ag Anti-cxcr5 antibodies and methods of use
WO2012019061A2 (en) 2010-08-05 2012-02-09 Stem Centrx, Inc. Novel effectors and methods of use
JP2013541937A (ja) 2010-08-05 2013-11-21 エフ．ホフマン−ラ ロシュ アーゲー 抗ｍｈｃ抗体−抗ウイルス性サイトカイン融合タンパク質
EP2603530B1 (en) 2010-08-13 2017-11-08 Roche Glycart AG Anti-fap antibodies and methods of use
CA2806640A1 (en) 2010-08-13 2012-02-16 Roche Glycart Ag Anti-tenascin-c a2 antibodies and methods of use
RU2013110875A (ru) 2010-08-24 2014-09-27 Ф.Хоффманн-Ля Рош Аг БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА, СОДЕРЖАЩИЕ СТАБИЛИЗИРОВАННЫЙ ДИСУЛЬФИДОМ ФРАГМЕНТ Fv
CN103080132B (zh) 2010-08-25 2016-06-08 弗·哈夫曼-拉罗切有限公司 抗il-18r1的抗体及其用途
US20130224191A1 (en) 2010-08-27 2013-08-29 Robert A. Stull Notum protein modulators and methods of use
SG188328A1 (en) 2010-09-03 2013-04-30 Stem Centrx Inc Novel modulators and methods of use
CA2813738A1 (en) 2010-10-05 2012-04-12 Genentech, Inc. Mutant smoothened and methods of using the same
TW201300417A (zh) 2010-11-10 2013-01-01 Genentech Inc 用於神經疾病免疫療法之方法及組合物
MX361929B (es) 2010-11-19 2018-12-19 Eisai R&D Man Co Ltd Star Anticuerpos anti-ligando de quimiocina cc 20 (ccl20) neutralizantes.
US9304134B2 (en) 2010-11-23 2016-04-05 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of anemia
US20140302034A1 (en) 2010-12-08 2014-10-09 Stem Centrx, Inc. Novel modulators and methods of use
CN112168962A (zh) 2010-12-16 2021-01-05 弗·哈夫曼-拉罗切有限公司 与th2抑制相关的诊断和治疗
US8911732B2 (en) 2010-12-20 2014-12-16 Genentech, Inc. Anti-mesothelin antibodies and immunoconjugates
US20120195910A1 (en) 2010-12-22 2012-08-02 Genentech, Inc. Anti-pcsk9 antibodies and methods of use
EP2655413B1 (en) 2010-12-23 2019-01-16 F.Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
EP2661282A1 (en) 2011-01-03 2013-11-13 F.Hoffmann-La Roche Ag A pharmaceutical composition of a complex of an anti-dig antibody and digoxigenin that is conjugated to a peptide
ES2579987T3 (es) 2011-02-10 2016-08-18 Roche Glycart Ag Polipéptidos interleuquina-2 mutantes
EP2672999A2 (en) 2011-02-10 2013-12-18 Roche Glycart AG Improved immunotherapy
SA112330278B1 (ar) 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
AR085403A1 (es) 2011-02-28 2013-09-25 Hoffmann La Roche Proteinas monovalentes que se unen a antigenos
EP2681239B8 (en) 2011-02-28 2015-09-09 F. Hoffmann-La Roche AG Antigen binding proteins
WO2012122512A1 (en) 2011-03-10 2012-09-13 Hco Antibody, Inc. Recombinant production of mixtures of single chain antibodies
EP2683735A1 (en) 2011-03-10 2014-01-15 HCO Antibody, Inc. Bispecific three-chain antibody-like molecules
MX2013010911A (es) 2011-03-23 2015-03-03 Pioneer Hi Bred Int Metodos para producir un locus de rasgo transgenico complejo.
WO2012130831A1 (en) 2011-03-29 2012-10-04 Roche Glycart Ag Antibody fc variants
KR20140021589A (ko) 2011-04-07 2014-02-20 제넨테크, 인크. 항-fgfr4 항체 및 사용 방법
CA2828662A1 (en) 2011-04-20 2012-10-26 Roche Glycart Ag Method and constructs for the ph dependent passage of the blood-brain-barrier
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
WO2012146630A1 (en) 2011-04-29 2012-11-01 F. Hoffmann-La Roche Ag N-terminal acylated polypeptides, methods for their production and uses thereof
WO2012155019A1 (en) 2011-05-12 2012-11-15 Genentech, Inc. Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature pepides
DK2710035T3 (en) 2011-05-16 2017-06-19 Hoffmann La Roche FGFR1 agonists and methods of use
KR101629073B1 (ko) 2011-06-15 2016-06-09 에프. 호프만-라 로슈 아게 항-인간 에리스로포이에틴 수용체 항체 및 이의 사용 방법
EP2723773B1 (en) 2011-06-22 2018-02-28 F. Hoffmann-La Roche AG Removal of target cells by circulating virus-specific cytotoxic t-cells using mhc class i comprising complexes
WO2013003680A1 (en) 2011-06-30 2013-01-03 Genentech, Inc. Anti-c-met antibody formulations
CN103917650B (zh) 2011-08-05 2017-10-24 瑞泽恩制药公司 人源化的通用轻链小鼠
KR20140057326A (ko) 2011-08-17 2014-05-12 제넨테크, 인크. 뉴레귤린 항체 및 그의 용도
AR087608A1 (es) 2011-08-23 2014-04-03 Roche Glycart Ag Moleculas biespecificas de union a antigeno activadoras de celulas t
WO2013026832A1 (en) 2011-08-23 2013-02-28 Roche Glycart Ag Anti-mcsp antibodies
JP6060162B2 (ja) 2011-08-23 2017-01-11 ロシュ グリクアート アーゲー ２つのＦａｂフラグメントを含むＦｃ不含抗体および使用方法
JP5925893B2 (ja) 2011-08-23 2016-05-25 ロシュ グリクアート アーゲー 二重特異性抗原結合分子
WO2013026837A1 (en) 2011-08-23 2013-02-28 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
RU2605390C2 (ru) 2011-08-23 2016-12-20 Рош Гликарт Аг Биспецифические антитела, специфичные к антигенам, активирующим т-клетки, и опухолевому антигену, и способы их применения
US20130058947A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc Novel Modulators and Methods of Use
WO2013040433A1 (en) 2011-09-15 2013-03-21 Genentech, Inc. Methods of promoting differentiation
CA2845147A1 (en) 2011-09-23 2013-03-28 Roche Glycart Ag Bispecific anti-egfr/anti igf-1r antibodies
MX2014004074A (es) 2011-10-05 2014-06-05 Genentech Inc Metodo de tratamiento de condiciones del higado utilizando antagonistas de notch2.
TW201321414A (zh) 2011-10-14 2013-06-01 Genentech Inc 抗－ＨｔｒＡ１抗體及其使用方法
MX2014004426A (es) 2011-10-15 2014-07-09 Genentech Inc Metodos de uso de antagonistas de scd1.
WO2013059531A1 (en) 2011-10-20 2013-04-25 Genentech, Inc. Anti-gcgr antibodies and uses thereof
US20140308301A1 (en) 2011-10-26 2014-10-16 The Regents Of The University Of California Cd44 monoclonal antibody for the treatment of b-cell chronic lymphocytic leukemia and other hematological malignancies
EP2776051A4 (en) 2011-10-28 2015-06-17 Hoffmann La Roche THERAPEUTIC COMBINATIONS AND METHOD FOR THE TREATMENT OF MELANOMA
EP3091029B1 (en) 2011-10-31 2022-12-28 F. Hoffmann-La Roche AG Anti-il13 antibody formulations
IN2014CN04183A (enExample) 2011-11-08 2015-07-17 Pfizer
SG11201402485UA (en) 2011-11-21 2014-06-27 Genentech Inc Purification of anti-c-met antibodies
MX350807B (es) 2011-11-29 2017-09-20 Genentech Inc Composiciones y metodos para el analisis de cancer de prostata.
US20140335084A1 (en) 2011-12-06 2014-11-13 Hoffmann-La Roche Inc. Antibody formulation
WO2013092720A1 (en) 2011-12-22 2013-06-27 F. Hoffmann-La Roche Ag Full length antibody display system for eukaryotic cells and its use
KR102229491B1 (ko) 2011-12-22 2021-03-18 에프. 호프만-라 로슈 아게 발현 벡터 구성원 조합, 신규한 제조 세포 생성 방법 및 폴리펩티드의 재조합적 제조를 위한 그의 용도
US9963511B2 (en) 2011-12-22 2018-05-08 Hoffmann-La Roche Inc. Expression vector organization, novel production cell generation methods and their use for the recombinant production of polypeptides
WO2013096791A1 (en) 2011-12-23 2013-06-27 Genentech, Inc. Process for making high concentration protein formulations
WO2013106485A2 (en) 2012-01-09 2013-07-18 The Scripps Research Institute Ultralong complementarity determining regions and uses thereof
EP3663314A1 (en) 2012-01-09 2020-06-10 The Scripps Research Institute Humanized antibodies with ultralong cdr3s
EP2804629A1 (en) 2012-01-18 2014-11-26 Genentech, Inc. Anti-lrp5 antibodies and methods of use
MX2014008699A (es) 2012-01-18 2014-11-21 Genentech Inc Metodos para utilizar moduladores de fgf19.
US9546219B2 (en) 2012-02-08 2017-01-17 North Carolina State University Treatment of allergic diseases with recombinant antibodies
EP2812357B1 (en) 2012-02-10 2020-11-04 F.Hoffmann-La Roche Ag Single-chain antibodies and other heteromultimers
RU2014133069A (ru) 2012-02-11 2016-04-10 Дженентек, Инк. Транслокации r-спондина и способы с их использованием
US20150018241A1 (en) 2012-02-15 2015-01-15 Hoffmann-La Roche Inc. Fc-receptor based affinity chromatography
PL2817338T3 (pl) 2012-02-24 2017-12-29 Abbvie Stemcentrx Llc Modulatory DLL3 i sposoby zastosowania
PL2822587T3 (pl) 2012-03-08 2016-07-29 Hoffmann La Roche Preparat przeciwciała abeta
BR112014024017A8 (pt) 2012-03-27 2017-07-25 Genentech Inc Métodos de tratamento de um tipo de câncer, de tratamento do carcinoma, para selecionar uma terapia e para quantificação e inibidor de her3
HK1206759A1 (en) 2012-03-28 2016-01-15 F. Hoffmann-La Roche Ag Anti-hcmv idiotypic antibodies and uses thereof
AR090549A1 (es) 2012-03-30 2014-11-19 Genentech Inc Anticuerpos anti-lgr5 e inmunoconjugados
ES2599386T3 (es) 2012-04-17 2017-02-01 F. Hoffmann-La Roche Ag Método para la expresión de polipéptidos usando ácidos nucleicos modificados
RS59263B1 (sr) 2012-04-20 2019-10-31 Merus Nv Postupci i sredstva za proizvodnju heterodimernih ig-sličnih molekula
MX2014012889A (es) 2012-05-01 2014-11-14 Genentech Inc Anticuerpos e inmunoconjugados anti-pmel17.
WO2013170191A1 (en) 2012-05-11 2013-11-14 Genentech, Inc. Methods of using antagonists of nad biosynthesis from nicotinamide
JP6294311B2 (ja) 2012-05-23 2018-03-14 ジェネンテック， インコーポレイテッド 治療薬の選択方法
EP2861624A1 (en) 2012-06-15 2015-04-22 F. Hoffmann-La Roche AG Anti-pcsk9 antibodies, formulations, dosing, and methods of use
WO2013186719A1 (en) 2012-06-15 2013-12-19 Pfizer Inc. Improved antagonist antibodies against gdf-8 and uses therefor
TW201402611A (zh) 2012-06-21 2014-01-16 Univ Indiana Res & Tech Corp 具有改變之ｆｃ效應子功能之腸促胰島素受體配體多肽ｆｃ區融合多肽及結合物
CA2871880A1 (en) 2012-06-27 2014-01-03 F. Hoffmann-La Roche Ag Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof
WO2014001326A1 (en) 2012-06-27 2014-01-03 F. Hoffmann-La Roche Ag Method for the selection and production of tailor-made, selective and multi-specific therapeutic molecules comprising at least two different targeting entities and uses thereof
WO2014001325A1 (en) 2012-06-27 2014-01-03 F. Hoffmann-La Roche Ag Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
MX353951B (es) 2012-07-04 2018-02-07 Hoffmann La Roche Anticuerpos de anti-teofilina y metodos de uso.
JP6148729B2 (ja) 2012-07-04 2017-06-14 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 共有結合している抗原−抗体結合体
EP2870180B1 (en) 2012-07-04 2024-08-28 F. Hoffmann-La Roche AG Anti-biotin antibodies and methods of use
BR112015000125A2 (en) 2012-07-05 2018-09-04 Genentech, Inc. molecules, vector, cells, process, protein, method for expressing an mbip polypeptide, polypeptides, antibody or antibody fragment and nucleotide sequence
PE20150615A1 (es) 2012-07-09 2015-05-28 Genentech Inc Inmunoconjugados que comprenden un anticuerpo anti-cd22 ligado a una pirrolobenzodiazepina
WO2014011520A1 (en) 2012-07-09 2014-01-16 Genentech, Inc. Immunoconjugates comprising anti-cd22 antibodies
CN104411337A (zh) 2012-07-09 2015-03-11 基因泰克公司 包含抗cd79b抗体的免疫偶联物
JP2015523380A (ja) 2012-07-09 2015-08-13 ジェネンテック， インコーポレイテッド 抗ｃｄ７９ｂ抗体を含む免疫複合体
HRP20181595T1 (hr) 2012-07-13 2018-12-14 Roche Glycart Ag Bispecifična anti-vegf/anti-ang-2 protutijela i njihova upotreba u liječenju očnih krvožilnih bolesti
SI2880170T1 (sl) 2012-08-02 2016-12-30 F. Hoffmann-La Roche Ag Postopek za proizvodnjo topnega FCR kot FC-fuzije z inertno imunoglobulinsko FC-regijo in uporabe le-tega
ES2848732T3 (es) 2012-08-07 2021-08-11 Roche Glycart Ag Inmunoterapia mejorada
WO2014023673A1 (en) 2012-08-08 2014-02-13 Roche Glycart Ag Interleukin-10 fusion proteins and uses thereof
JP2015525792A (ja) 2012-08-09 2015-09-07 ロシュ グリクアート アクチェンゲゼルシャフト Ａｓｇｐｒ抗体およびその使用
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
BR112015003938A2 (pt) 2012-09-14 2018-09-04 Hoffmann La Roche métodos de produção de polipeptídeos, de produção de aglutinantes multiespecíficos, de seleção de aglutinantes multiespecíficos, de seleção de anticorpos biespecíficos e de determinação de combinação, anticorpo biespecífico, formulação farmcêutica e uso de anticorpo biespecífico
MX2015003616A (es) 2012-10-08 2015-06-05 Roche Glycart Ag Anticuerpos sin fc que comprenden dos fragmentos fab y metodos de uso.
US9725512B2 (en) 2012-11-08 2017-08-08 Hoffmann-La Roche Inc. HER3 antibodies binding to the beta-hairpin of HER3
EA201892509A1 (ru) 2012-11-13 2019-04-30 Дженентек, Инк. Антитела к гемагглютинину и способы применения
WO2014096015A1 (en) 2012-12-21 2014-06-26 F. Hoffmann-La Roche Ag Disulfide-linked multivalent mhc class i comprising multi-function proteins
WO2014107739A1 (en) 2013-01-07 2014-07-10 Eleven Biotherapeutics, Inc. Antibodies against pcsk9
WO2014116749A1 (en) 2013-01-23 2014-07-31 Genentech, Inc. Anti-hcv antibodies and methods of using thereof
JP2016512489A (ja) 2013-02-26 2016-04-28 ロシュ グリクアート アーゲー 抗ｍｃｓｐ抗体
MX375359B (es) 2013-02-26 2025-03-06 Roche Glycart Ag Moléculas biespecíficas de unión a antígeno activadoras de células t.
CA2896359A1 (en) 2013-02-26 2014-09-04 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
BR112015017800A2 (pt) 2013-02-26 2017-11-21 Roche Glycart Ag moléculas de ligação ao antígeno biespecífica ativadora de célula t, polinucleotídeo, polipeptídeo, vetor, célula hospedeira, método de produção da molécula de ligação ao antígeno biespecífica ativadora de célula t, composição farmacêutica e uso da molécula de ligação ao antígeno biespecífica ativadora de célula t
PL2968466T3 (pl) 2013-03-13 2018-11-30 F.Hoffmann-La Roche Ag Preparaty o zmniejszonym utlenianiu
US10653779B2 (en) 2013-03-13 2020-05-19 Genentech, Inc. Formulations with reduced oxidation
US20140314778A1 (en) 2013-03-13 2014-10-23 Genentech, Inc. Formulations with reduced oxidation
HUE049707T2 (hu) 2013-03-13 2020-11-30 Hoffmann La Roche Csökkent oxidációjú kiszerelések
EP2968553B1 (en) 2013-03-13 2020-08-12 F.Hoffmann-La Roche Ag Antibody formulations
US9562099B2 (en) 2013-03-14 2017-02-07 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
EP2970474B1 (en) 2013-03-14 2017-12-20 Genentech, Inc. Anti-b7-h4 antibodies and immunoconjugates
SG11201507477XA (en) 2013-03-14 2015-10-29 Genentech Inc Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use
KR20210037745A (ko) 2013-03-15 2021-04-06 제넨테크, 인크. 항산화제를 함유하는 세포 배양 조성물 및 폴리펩티드 생산 방법
CA2903589A1 (en) 2013-03-15 2014-09-18 Genentech, Inc. Cell culture media and methods of antibody production
RU2661111C2 (ru) 2013-03-15 2018-07-11 Ац Иммуне С.А. Антитела к тау и способы применения
US20140328849A1 (en) 2013-03-15 2014-11-06 Genentech, Inc. Anti-crth2 antibodies and methods of use
AU2014236815B2 (en) 2013-03-15 2019-04-04 Genentech, Inc. Compositions and methods for diagnosis and treatment of hepatic cancers
HK1218424A1 (zh) 2013-03-15 2017-02-17 F. Hoffmann-La Roche Ag Il-22多肽和il-22 fc融合蛋白及其使用方法
UA118028C2 (uk) 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
EP2983710B1 (en) 2013-04-09 2019-07-31 Annexon, Inc. Methods of treatment for neuromyelitis optica
ES2871383T3 (es) 2013-04-29 2021-10-28 Hoffmann La Roche Anticuerpos asimétricos modificados que se unen al receptor de Fc y procedimientos de uso
WO2014177461A1 (en) 2013-04-29 2014-11-06 F. Hoffmann-La Roche Ag Fcrn-binding abolished anti-igf-1r antibodies and their use in the treatment of vascular eye diseases
EP2992012B1 (en) 2013-04-29 2019-07-17 F.Hoffmann-La Roche Ag Human fcrn-binding modified antibodies and methods of use
AR096364A1 (es) 2013-05-20 2015-12-23 Genentech Inc Anticuerpos receptores de antitransferina y métodos de uso
MX375500B (es) 2013-07-09 2025-03-06 Annexon Inc Anticuerpos anti-factor del complemento c1q y uso de los mismos.
EP3022224A2 (en) 2013-07-18 2016-05-25 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
CA2918370A1 (en) 2013-07-18 2015-01-22 Fabrus, Inc. Humanized antibodies with ultralong complementarity determining regions
EP2832854A1 (en) 2013-08-02 2015-02-04 F. Hoffmann-La Roche AG Method for improving the recombinant expression of a polypeptide by C-terminal fusion to human neprilysin
US10442836B2 (en) 2013-08-12 2019-10-15 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1H-benzo[E]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
CA2922089C (en) 2013-08-22 2022-07-05 E. I. Du Pont De Nemours And Company Plant genome modification using guide rna/cas endonuclease systems and methods of use
RU2016111139A (ru) 2013-08-28 2017-10-03 ЭББВИ СТЕМСЕНТРКС ЭлЭлСи Новые модуляторы sez6 и способы их применения
KR20160055252A (ko) 2013-09-17 2016-05-17 제넨테크, 인크. 항-lgr5 항체의 사용 방법
WO2015044083A1 (en) 2013-09-27 2015-04-02 F. Hoffmann-La Roche Ag Thermus thermophilus slyd fkbp domain specific antibodies
PT3049441T (pt) 2013-09-27 2020-01-21 Hoffmann La Roche Formulações de anticorpos anti-pdl1
WO2015052230A1 (en) 2013-10-11 2015-04-16 F. Hoffmann-La Roche Ag Multispecific domain exchanged common variable light chain antibodies
MX2016004573A (es) 2013-10-11 2016-07-21 Genentech Inc Inhibidores de nsp4 y metodos de uso.
BR112016008477A2 (pt) 2013-10-18 2017-10-03 Genentech Inc Corpos, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica e usos do anticorpo
SG11201603127WA (en) 2013-10-23 2016-05-30 Genentech Inc Methods of diagnosing and treating eosinophilic disorders
JP2016538283A (ja) 2013-11-13 2016-12-08 ザイムワークス，インコーポレイテッド Ｅｇｆｒ及び／またはｈｅｒ２を標的にする一価抗原結合性構築物及びその使用
RU2697098C1 (ru) 2013-11-21 2019-08-12 Ф.Хоффманн-Ля Рош Аг Антитела к альфа-синуклеину и способы применения
RU2737882C2 (ru) 2013-11-27 2020-12-04 Займворкс Инк. Биспецифические антигенсвязывающие конструкции против her2
SG11201604784XA (en) 2013-12-13 2016-07-28 Genentech Inc Anti-cd33 antibodies and immunoconjugates
MX2016007578A (es) 2013-12-16 2016-10-03 Genentech Inc Compuestos de conjugado anticuerpo-farmaco dimerico de 1-(clorometil)-2,3-dihidro-1h-benzo [e] indol, y metodos de uso y tratamiento.
US20150190506A1 (en) 2013-12-17 2015-07-09 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
EP3647324A1 (en) 2013-12-17 2020-05-06 F. Hoffmann-La Roche AG Methods of treating cancers using pd-1 axis binding antagonists and taxanes
EP3083690A1 (en) 2013-12-17 2016-10-26 F.Hoffmann-La Roche Ag Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody
LT3083680T (lt) 2013-12-20 2020-04-10 F. Hoffmann-La Roche Ag Humanizuoti anti-tau(ps422) antikūnai ir jų naudojimo būdai
US10137170B2 (en) 2013-12-20 2018-11-27 Indiana University Research And Technology Corporation Lipidated incretin receptor ligand human immunoglobulin Fc-region fusion polypeptides
TWI728373B (zh) 2013-12-23 2021-05-21 美商建南德克公司 抗體及使用方法
CN105873615B (zh) 2014-01-03 2020-12-25 豪夫迈·罗氏有限公司 共价连接的helicar-抗helicar抗体缀合物及其用途
EP3089759B1 (en) 2014-01-03 2018-12-05 F. Hoffmann-La Roche AG Covalently linked polypeptide toxin-antibody conjugates
KR20160104628A (ko) 2014-01-03 2016-09-05 에프. 호프만-라 로슈 아게 이중특이성 항-합텐/항-혈액뇌장벽 수용체 항체, 그의 복합체 및 혈액뇌장벽 셔틀로서 그의 용도
EP3851452A1 (en) 2014-01-06 2021-07-21 F. Hoffmann-La Roche AG Monovalent blood brain barrier shuttle modules
JP6786392B2 (ja) 2014-01-15 2020-11-18 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ＦｃＲｎ結合特性が改変され、プロテインＡ結合特性が保持されているＦｃ領域変異体
AU2015209154A1 (en) 2014-01-24 2017-02-16 Genentech, Inc. Methods of using anti-STEAP1 antibodies and immunoconjugates
DK3102197T3 (en) 2014-02-04 2018-11-19 Genentech Inc Smoothened mutant and methods for its use
EA034350B1 (ru) 2014-02-06 2020-01-30 Ф.Хоффманн-Ля Рош Аг Слитые белки, содержащие интерлейкин-2, и их применения
BR112016018170A2 (pt) 2014-02-08 2018-02-20 Genentech, Inc. métodos para tratar doença de alzheimer
AU2015213741B2 (en) 2014-02-08 2020-10-08 Genentech, Inc. Methods of treating Alzheimer's Disease
JP6571115B2 (ja) 2014-02-12 2019-09-04 ジェネンテック， インコーポレイテッド 抗ｊａｇｇｅｄ１抗体及び使用方法
EP3107574A2 (en) 2014-02-21 2016-12-28 F. Hoffmann-La Roche AG Anti-il-13/il-17 bispecific antibodies and uses thereof
CN106103478B (zh) 2014-03-21 2020-04-03 豪夫迈·罗氏有限公司 抗体体内半寿期的体外预测
WO2015140591A1 (en) 2014-03-21 2015-09-24 Nordlandssykehuset Hf Anti-cd14 antibodies and uses thereof
WO2015143414A2 (en) 2014-03-21 2015-09-24 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
RU2710551C2 (ru) 2014-03-25 2019-12-27 Дженентек, Инк. Способы приготовления полоксамера для применения в клеточной культуральной среде
JP6637439B2 (ja) 2014-03-31 2020-01-29 ジェネンテック， インコーポレイテッド 抗ｏｘ４０抗体及び使用方法
AU2015241038A1 (en) 2014-03-31 2016-10-13 Genentech, Inc. Combination therapy comprising anti-angiogenesis agents and OX40 binding agonists
KR102376287B1 (ko) 2014-04-02 2022-03-17 에프. 호프만-라 로슈 아게 다중특이적 항체 경쇄 잘못짝짓기의 검출 방법
WO2015164615A1 (en) 2014-04-24 2015-10-29 University Of Oslo Anti-gluten antibodies and uses thereof
MX2016015162A (es) 2014-05-22 2017-03-03 Genentech Inc Anticuerpos anti - gpc3 e inmunoconjugados.
EP3146071B1 (en) 2014-05-23 2020-09-02 F. Hoffmann-La Roche AG Mit biomarkers and methods using the same
WO2015191715A1 (en) 2014-06-11 2015-12-17 Genentech, Inc. Anti-lgr5 antibodies and uses thereof
JP6654581B2 (ja) 2014-06-26 2020-02-26 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 抗ｂｒｄｕ抗体および使用方法
AR100978A1 (es) 2014-06-26 2016-11-16 Hoffmann La Roche LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
BR112017000497B1 (pt) 2014-07-11 2023-12-26 Ventana Medical Systems, Inc Anticorpo isolado, célula hospedeira procariótica, imunoconjugado e método de detecção da presença ou do nível de expressão de pd-l1
WO2016007775A1 (en) 2014-07-11 2016-01-14 Genentech, Inc. Notch pathway inhibition
JP6464255B2 (ja) 2014-08-04 2019-02-06 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 二重特異性ｔ細胞活性化抗原結合分子
SG11201700901SA (en) 2014-08-08 2017-03-30 Alector Llc Anti-trem2 antibodies and methods of use thereof
WO2016040825A1 (en) 2014-09-12 2016-03-17 Genentech, Inc. Anthracycline disulfide intermediates, antibody-drug conjugates and methods
EP3191520B1 (en) 2014-09-12 2020-01-01 Genentech, Inc. Anti-cll-1 antibodies and immunoconjugates
EP3191518B1 (en) 2014-09-12 2020-01-15 Genentech, Inc. Anti-b7-h4 antibodies and immunoconjugates
WO2016040030A1 (en) 2014-09-12 2016-03-17 E. I. Du Pont De Nemours And Company Generation of site-specific-integration sites for complex trait loci in corn and soybean, and methods of use
PL3191135T3 (pl) 2014-09-12 2021-01-25 Genentech, Inc. Przeciwciała i immunokoniugaty anty-HER2
EP3193932B1 (en) 2014-09-15 2023-04-26 F. Hoffmann-La Roche AG Antibody formulations
WO2016042412A1 (en) 2014-09-16 2016-03-24 Symphogen A/S Anti-met antibodies and compositions
HK1243629A1 (zh) 2014-09-17 2018-07-20 基因泰克公司 包含抗her2抗体和吡咯并苯并二氮杂䓬的免疫缀合物
RS60349B8 (sr) 2014-09-23 2022-10-31 Hoffmann La Roche Postupak upotrebe anti-cd79b imunokonjugata
JP2017536102A (ja) 2014-10-16 2017-12-07 ジェネンテック， インコーポレイテッド 抗アルファ−シヌクレイン抗体及び使用方法
KR20170074246A (ko) 2014-11-03 2017-06-29 제넨테크, 인크. Ox40 효능제 치료의 효능 예측 및 평가용 방법 및 바이오마커
KR20170086540A (ko) 2014-11-03 2017-07-26 제넨테크, 인크. T 세포 면역 하위세트를 검출하기 위한 검정 및 그의 사용 방법
AU2015343029B2 (en) 2014-11-05 2021-07-29 Annexon, Inc. Humanized anti-complement factor C1q antibodies and uses thereof
KR20170076697A (ko) 2014-11-06 2017-07-04 에프. 호프만-라 로슈 아게 개질된 FCRN-결합 특성 및 단백질 A-결합 특성을 가진 Fc-영역 변이체
DK3215528T3 (da) 2014-11-06 2019-10-07 Hoffmann La Roche Fc-regionvarianter med modificeret FcRn-binding og anvendelsesfremgangsmåder
WO2016073157A1 (en) 2014-11-06 2016-05-12 Genentech, Inc. Anti-ang2 antibodies and methods of use thereof
JP2018500882A (ja) 2014-11-10 2018-01-18 ジェネンテック， インコーポレイテッド 腎症の動物モデルおよびそれを治療するための薬剤
MX2017006094A (es) 2014-11-10 2017-07-19 Genentech Inc Anticuerpos anti-interleucina-33 y sus usos.
CA2963718A1 (en) 2014-11-14 2016-05-19 F. Hoffmann-La Roche Ag Antigen binding molecules comprising a tnf family ligand trimer
KR20170096112A (ko) 2014-11-17 2017-08-23 제넨테크, 인크. Ox40 결합 효능제 및 pd-1 축 결합 길항제를 포함하는 조합 요법
EP3221361B1 (en) 2014-11-19 2021-04-21 Genentech, Inc. Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use
WO2016081643A1 (en) 2014-11-19 2016-05-26 Genentech, Inc. Anti-transferrin receptor antibodies and methods of use
EP3221364B1 (en) 2014-11-19 2020-12-16 Genentech, Inc. Antibodies against bace1 and use thereof for neural disease immunotherapy
HRP20201156T1 (hr) 2014-11-20 2020-11-13 F. Hoffmann - La Roche Ag Zajednički laki lanci i postupci primjene
SG11201704056XA (en) 2014-11-20 2017-06-29 Hoffmann La Roche Combination therapy of t cell activating bispecific antigen binding molecules cd3 abd folate receptor 1 (folr1) and pd-1 axis binding antagonists
EP3223848B1 (en) 2014-11-27 2024-11-27 Zymeworks BC Inc. Methods of using bispecific antigen-binding constructs targeting her2
EP3227332B1 (en) 2014-12-03 2019-11-06 F.Hoffmann-La Roche Ag Multispecific antibodies
RS59203B1 (sr) 2014-12-05 2019-10-31 Hoffmann La Roche Anti-cd79b antitela i postupci primene
BR112017011234A2 (pt) 2014-12-10 2018-03-27 Genentech Inc anticorpos contra receptor da barreira hematoencefálica e métodos de uso
CN107001447B (zh) 2014-12-17 2021-07-23 豪夫迈·罗氏有限公司 采用分选酶的酶介导多肽缀合新方法
KR20170094787A (ko) 2014-12-18 2017-08-21 에프. 호프만-라 로슈 아게 Cdc 유발 항체를 측정하기 위한 검정 및 방법
AR103162A1 (es) 2014-12-19 2017-04-19 Chugai Pharmaceutical Co Ltd Anticuerpos anti-c5 y métodos para su uso
AR103161A1 (es) 2014-12-19 2017-04-19 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina y regiones fc variantes así como métodos de uso
US20180016327A1 (en) 2015-01-22 2018-01-18 Chugai Seiyaku Kabushiki Kaisha A Combination of Two or More Anti-C5 Antibodies and Methods of Use
AU2016215227A1 (en) 2015-02-04 2017-09-21 Assistance Publique-Hopitaux De Paris Mutant smoothened and methods of using the same
EP3816179A3 (en) 2015-02-05 2021-08-04 Chugai Seiyaku Kabushiki Kaisha Fc region variant comprising a modified fcrn-binding domain
HK1247287A1 (zh) 2015-03-16 2018-09-21 F. Hoffmann-La Roche Ag 检测和定量il-13的方法和在诊断和治疗th2相关疾病中的用途
WO2016146833A1 (en) 2015-03-19 2016-09-22 F. Hoffmann-La Roche Ag Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance
EP3271403A1 (en) 2015-03-19 2018-01-24 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
US10450576B2 (en) 2015-03-27 2019-10-22 E I Du Pont De Nemours And Company Soybean U6 small nuclear RNA gene promoters and their use in constitutive expression of small RNA genes in plants
HRP20211980T1 (hr) 2015-04-07 2022-04-01 Alector Llc Protutijela protiv sortilina i postupci njihove upotrebe
BR112017022255A2 (pt) 2015-04-17 2018-08-28 Centre Nat Rech Scient anticorpo humanizado ou humano isolado, molécula de ácido nucleico isolada, vetor, célula hospedeira, método para produzir um anticorpo, e composição farmacêutica
JP6815331B2 (ja) 2015-04-21 2021-01-20 ジェネンテック， インコーポレイテッド 前立腺がんの分析のための組成物及び方法
CN115932273A (zh) 2015-04-24 2023-04-07 豪夫迈·罗氏有限公司 鉴定包含结合多肽的细菌的方法
CN107709363A (zh) 2015-05-01 2018-02-16 基因泰克公司 掩蔽抗cd3抗体和使用方法
EP3936524A3 (en) 2015-05-11 2022-06-15 F. Hoffmann-La Roche AG Compositions and methods of treating lupus nephritis
ES2810700T3 (es) 2015-05-29 2021-03-09 Hoffmann La Roche Metilación del promotor de PD-L1 en cáncer
HK1250723A1 (zh) 2015-05-29 2019-01-11 F. Hoffmann-La Roche Ag 人源化抗埃博拉病毒糖蛋白抗体和使用方法
EP3302552A1 (en) 2015-06-02 2018-04-11 H. Hoffnabb-La Roche Ag Compositions and methods for using anti-il-34 antibodies to treat neurological diseases
SG10201911349YA (en) 2015-06-05 2020-01-30 Genentech Inc Anti-tau antibodies and methods of use
HK1252272A1 (zh) 2015-06-08 2019-05-24 豪夫迈‧罗氏有限公司 使用抗ox40抗体治疗癌症的方法
KR20180025888A (ko) 2015-06-08 2018-03-09 제넨테크, 인크. 항-ox40 항체 및 pd-1 축 결합 길항제를 사용하여 암을 치료하는 방법
JP7376977B2 (ja) 2015-06-12 2023-11-09 アレクトル エルエルシー 抗ｃｄ３３抗体及びその使用方法
WO2016201389A2 (en) 2015-06-12 2016-12-15 Alector Llc Anti-cd33 antibodies and methods of use thereof
AR104987A1 (es) 2015-06-15 2017-08-30 Genentech Inc Inmunoconjugados anticuerpo-fármaco unidos por enlazadores no peptídicos
TW201718647A (zh) 2015-06-16 2017-06-01 建南德克公司 抗-cll-1抗體及使用方法
KR20250021639A (ko) 2015-06-16 2025-02-13 제넨테크, 인크. FcRH5에 대한 인간화 및 친화도 성숙 항체 및 사용방법
CN107849145B (zh) 2015-06-16 2021-10-26 基因泰克公司 抗cd3抗体及其使用方法
PL3310812T3 (pl) 2015-06-17 2025-11-03 F. Hoffmann-La Roche Ag Przeciwciała anty-her2 i sposoby stosowania
JP6896650B2 (ja) 2015-06-17 2021-06-30 ジェネンテック， インコーポレイテッド Ｐｄ−１軸結合アンタゴニスト及びタキサンを使用した局所進行性または転移性乳癌の治療方法
US9862763B2 (en) 2015-06-24 2018-01-09 Hoffmann-La Roche Inc. Humanized anti-tau(pS422) antibodies and methods of use
UA127809C2 (uk) 2015-06-24 2024-01-10 Ф. Хоффманн-Ля Рош Аг Антитіло до рецептора трансферину зі спеціально підібраною афінністю
WO2016207091A1 (en) 2015-06-24 2016-12-29 F. Hoffmann-La Roche Ag Trispecific antibodies specific for her2 and a blood brain barrier receptor and methods of use
US20170029520A1 (en) 2015-06-29 2017-02-02 Genentech, Inc. Compositions and methods for use in organ transplantation
WO2017001350A1 (en) 2015-06-29 2017-01-05 Ventana Medical Systems, Inc. Materials and methods for performing histochemical assays for human pro-epiregulin and amphiregulin
SI3124976T1 (sl) 2015-07-28 2018-12-31 F. Hoffmann-La Roche Ag Izboljšan test bakterijskih endotoksinov za določanje endotoksinov
TW202440903A (zh) 2015-08-04 2024-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法（一）
HK1252696A1 (zh) 2015-08-28 2019-05-31 艾利妥 抗siglec-7抗体及其使用方法
UA120981C2 (uk) 2015-09-18 2020-03-10 Чугаі Сейяку Кабусікі Кайся Антитіло, що зв'язується з il-8, та його застосування
EP3353206A1 (en) 2015-09-22 2018-08-01 Spring Bioscience Corporation Anti-ox40 antibodies and diagnostic uses thereof
MA42924A (fr) 2015-09-23 2018-08-01 Hoffmann La Roche Variants optimisés d'anticorps anti-vegf
WO2017053906A1 (en) 2015-09-24 2017-03-30 Abvitro Llc Hiv antibody compositions and methods of use
SMT202500003T1 (it) 2015-09-25 2025-03-12 Hoffmann La Roche Anticorpi anti-tigit e procedimenti di utilizzo
CN108138158B (zh) 2015-09-25 2021-11-09 豪夫迈·罗氏有限公司 可溶性分选酶a
EP3353314A1 (en) 2015-09-25 2018-08-01 H. Hoffnabb-La Roche Ag Transamidation employing sortase a in deep eutectic solvents
WO2017050889A1 (en) 2015-09-25 2017-03-30 F. Hoffmann-La Roche Ag Recombinant immunoglobulin heavy chains comprising a sortase conjugation loop and conjugates thereof
EP3353310B1 (en) 2015-09-25 2020-04-29 H. Hoffnabb-La Roche Ag Process for producing thioesters employing a sortase a
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
US20180282410A1 (en) 2015-10-02 2018-10-04 Hoffmann-La Roche Inc. Anti-cd3xrob04 bispecific t cell activating antigen binding molecules
CR20180161A (es) 2015-10-02 2018-05-25 Hoffmann La Roche Anticuerpos biespecíficos para pd1 y tim3
WO2017055392A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Anti-cd3xcd44v6 bispecific t cell activating antigen binding molecules
WO2017055388A2 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Bispecific t cell activating antigen binding molecules
KR20250052494A (ko) 2015-10-02 2025-04-18 에프. 호프만-라 로슈 아게 이중특이성 항-인간 cd20/인간 트랜스페린 수용체 항체 및 사용 방법
CA2990755A1 (en) 2015-10-02 2017-04-06 F. Hoffman-La Roche Ag Bispecific anti-ceaxcd3 t cell activating antigen binding molecules
WO2017055393A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Anti-cd3xtim-3 bispecific t cell activating antigen binding molecules
CN108026177B (zh) 2015-10-02 2021-11-26 豪夫迈·罗氏有限公司 双特异性抗cd19xcd3 t细胞活化性抗原结合分子
RU2746409C1 (ru) 2015-10-02 2021-04-13 Ф. Хоффманн-Ля Рош Аг Антитела к pd1 и способы их применения
EP3150636A1 (en) 2015-10-02 2017-04-05 F. Hoffmann-La Roche AG Tetravalent multispecific antibodies
JP2018536389A (ja) 2015-10-02 2018-12-13 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト メソテリンとｃｄ３に結合する二重特異性細胞活性化抗原結合分子
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
CN108602887B (zh) 2015-10-02 2022-06-21 豪夫迈·罗氏有限公司 对共刺激性tnf受体特异性的双特异性抗体
WO2017055385A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Anti-cd3xgd2 bispecific t cell activating antigen binding molecules
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
KR20180068999A (ko) 2015-10-06 2018-06-22 알렉터 엘엘씨 항-trem2 항체 및 그의 사용방법
CR20180171A (es) 2015-10-07 2018-05-03 Hoffmann La Roche Anticuerpos biespecíficos con tetravalencia para un receptor de fnt coestimulador
MA45326A (fr) 2015-10-20 2018-08-29 Genentech Inc Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
WO2017075432A2 (en) 2015-10-29 2017-05-04 Alector Llc Anti-siglec-9 antibodies and methods of use thereof
JP6949016B2 (ja) 2015-10-29 2021-10-13 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 抗バリアントＦｃ領域抗体および使用法
EP3184547A1 (en) 2015-10-29 2017-06-28 F. Hoffmann-La Roche AG Anti-tpbg antibodies and methods of use
CN108289951A (zh) 2015-10-30 2018-07-17 豪夫迈·罗氏有限公司 抗-因子d抗体和缀合物
EP4036120A1 (en) 2015-10-30 2022-08-03 F. Hoffmann-La Roche AG Hinge modified antibody fragments and methods of making
CN108290957B (zh) 2015-10-30 2022-06-17 豪夫迈·罗氏有限公司 抗-HtrA1抗体及其使用方法
EP3371217B1 (en) 2015-11-08 2025-06-11 F. Hoffmann-La Roche AG Methods of screening for multispecific antibodies
UA123774C2 (uk) 2015-12-18 2021-06-02 Чугаі Сейяку Кабусікі Кайся Антитіла проти c5 та способи застосування
CN115028721A (zh) 2015-12-18 2022-09-09 中外制药株式会社 抗-肌肉生长抑制因子抗体、包含变体fc区的多肽及使用方法
IL299759A (en) 2015-12-30 2023-03-01 Genentech Inc Formulations with reduced polysorbate dissolution
SG11201804951SA (en) 2015-12-30 2018-07-30 Genentech Inc Use of tryptophan derivatives for protein formulations
CN108368179B (zh) 2016-01-08 2022-08-23 豪夫迈·罗氏有限公司 使用pd-1轴结合拮抗剂和抗cea/抗cd3双特异性抗体治疗cea阳性癌症的方法
CN114113625A (zh) 2016-01-20 2022-03-01 基因泰克公司 用于阿尔茨海默氏病的高剂量治疗
EP3411396A1 (en) 2016-02-04 2018-12-12 Curis, Inc. Mutant smoothened and methods of using the same
EP3423493A2 (en) 2016-03-04 2019-01-09 Alector LLC Anti-trem1 antibodies and methods of use thereof
US11357849B2 (en) 2016-03-07 2022-06-14 Musc Foundation For Research Development Anti-nucleolin antibodies
US12128102B2 (en) 2016-03-08 2024-10-29 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins
MX2018010546A (es) 2016-03-15 2019-02-20 Chugai Pharmaceutical Co Ltd Metodos de tratamiento de cancer que usan antagonistas de union al eje de muerte programada 1 (pd-1) y anticuerpos anti glipicano 3 (gpc3).
KR102444614B1 (ko) 2016-03-22 2022-09-21 에프. 호프만-라 로슈 아게 프로테아제-활성화된 t 세포 이중특이적 분자
US20170315132A1 (en) 2016-03-25 2017-11-02 Genentech, Inc. Multiplexed total antibody and antibody-conjugated drug quantification assay
EP3231813A1 (en) 2016-03-29 2017-10-18 F. Hoffmann-La Roche AG Trimeric costimulatory tnf family ligand-containing antigen binding molecules
WO2017167712A1 (en) 2016-03-30 2017-10-05 F. Hoffmann-La Roche Ag Improved sortase
EP3443004A1 (en) 2016-04-14 2019-02-20 H. Hoffnabb-La Roche Ag Anti-rspo3 antibodies and methods of use
KR102523682B1 (ko) 2016-05-02 2023-04-19 에프. 호프만-라 로슈 아게 콘톨스바디 - 단쇄 표적 결합제
EP3455254B1 (en) 2016-05-11 2021-07-07 F. Hoffmann-La Roche AG Antigen binding molecules comprising a tnf family ligand trimer and a tenascin binding moiety
WO2017194441A1 (en) 2016-05-11 2017-11-16 F. Hoffmann-La Roche Ag Modified anti-tenascin antibodies and methods of use
EP3243836A1 (en) 2016-05-11 2017-11-15 F. Hoffmann-La Roche AG C-terminally fused tnf family ligand trimer-containing antigen binding molecules
EP3243832A1 (en) 2016-05-13 2017-11-15 F. Hoffmann-La Roche AG Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
CN109152843A (zh) 2016-05-20 2019-01-04 豪夫迈·罗氏有限公司 Protac抗体缀合物及其使用方法
EP3465221B1 (en) 2016-05-27 2020-07-22 H. Hoffnabb-La Roche Ag Bioanalytical method for the characterization of site-specific antibody-drug conjugates
JP7043425B2 (ja) 2016-06-06 2022-03-29 ジェネンテック， インコーポレイテッド シルベストロール抗体－薬物コンジュゲート及び使用方法
CA3025995C (en) 2016-06-06 2023-08-08 F. Hoffmann-La Roche Ag Fusion proteins for ophthalmology with increased eye retention
MY193497A (en) 2016-06-17 2022-10-17 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies and methods of use
EP3475298A1 (en) 2016-06-24 2019-05-01 H. Hoffnabb-La Roche Ag Anti-polyubiquitin multispecific antibodies
WO2018007314A1 (en) 2016-07-04 2018-01-11 F. Hoffmann-La Roche Ag Novel antibody format
US20190185578A1 (en) 2016-07-29 2019-06-20 Chugai Seiyaku Kabushiki Kaisha Bispecific antibody exhibiting increased alternative fviii-cofactor-function activity
CN116251182A (zh) 2016-08-05 2023-06-13 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
WO2018029124A1 (en) 2016-08-08 2018-02-15 F. Hoffmann-La Roche Ag Therapeutic and diagnostic methods for cancer
JP2020501506A (ja) 2016-09-07 2020-01-23 イッサム リサーチ デベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム エルティーディー． 抗ＮＫｐ４６抗体およびその治療的使用
WO2018049083A1 (en) 2016-09-07 2018-03-15 The Regents Of The University Of California Antibodies to oxidation-specific epitopes
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
JP6976315B2 (ja) 2016-09-19 2021-12-08 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 補体因子に基づくアフィニティークロマトグラフィー
KR102557643B1 (ko) 2016-09-23 2023-07-20 제넨테크, 인크. 아토피성 피부염을 치료하기 위한 il-13 길항제의 용도
WO2018060301A1 (en) 2016-09-30 2018-04-05 F. Hoffmann-La Roche Ag Bispecific antibodies against cd3
JP7050770B2 (ja) 2016-10-05 2022-04-08 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗体薬物コンジュゲートの調製方法
EP3532091A2 (en) 2016-10-29 2019-09-04 H. Hoffnabb-La Roche Ag Anti-mic antibidies and methods of use
WO2018089335A1 (en) 2016-11-09 2018-05-17 North Carolina State University Treatment of allergic diseases with chimeric protein
TW201829463A (zh) 2016-11-18 2018-08-16 瑞士商赫孚孟拉羅股份公司 抗hla-g抗體及其用途
KR102221364B1 (ko) 2016-11-21 2021-03-04 쿠레아브 게엠베하 항-gp73　항체　및　면역접합체
KR102645073B1 (ko) 2016-12-07 2024-03-11 제넨테크, 인크. 항-타우 항체 및 이의 이용 방법
WO2018106781A1 (en) 2016-12-07 2018-06-14 Genentech, Inc Anti-tau antibodies and methods of use
JP7125400B2 (ja) 2016-12-19 2022-08-24 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 標的化４－１ｂｂ（ｃｄ１３７）アゴニストとの併用療法
KR102692708B1 (ko) 2016-12-20 2024-08-07 에프. 호프만-라 로슈 아게 항-cd20/항-cd3 이중특이성 항체 및 4-1bb(cd137) 작용물질의 병용 요법
JP6931058B2 (ja) 2016-12-21 2021-09-01 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 抗体のインビトロ糖鎖工学における酵素の再使用
CN110088291A (zh) 2016-12-21 2019-08-02 豪夫迈·罗氏有限公司 用于体外糖工程化抗体的方法
EP3559249A1 (en) 2016-12-21 2019-10-30 H. Hoffnabb-La Roche Ag Method for in vitro glycoengineering of antibodies
KR20190099527A (ko) 2017-01-03 2019-08-27 에프. 호프만-라 로슈 아게 항-4-1bb 클론 20h4.9를 포함하는 이중특이성 항원 결합 분자
AU2018211064A1 (en) 2017-01-18 2019-09-05 Genentech, Inc. Idiotypic antibodies against anti-PD-L1 antibodies and uses thereof
EP3580240A1 (en) 2017-02-10 2019-12-18 H. Hoffnabb-La Roche Ag Anti-tryptase antibodies, compositions thereof, and uses thereof
JP7021245B2 (ja) 2017-03-10 2022-02-16 エフ．ホフマン－ラ ロシュ アーゲー 多重特異性抗体を生産するための方法
JP7216006B2 (ja) 2017-03-22 2023-01-31 ジェネンテック， インコーポレイテッド ヒドロゲル架橋ヒアルロン酸プロドラッグ組成物及び方法
CR20190481A (es) 2017-03-22 2020-01-06 Genentech Inc Composiciones de anticuerpo optimizados para el tratamiento de trastornos oculares
EP3601337A1 (en) 2017-03-28 2020-02-05 Genentech, Inc. Methods of treating neurodegenerative diseases
WO2018178074A1 (en) 2017-03-29 2018-10-04 F. Hoffmann-La Roche Ag Trimeric antigen binding molecules specific for a costimulatory tnf receptor
WO2018178055A1 (en) 2017-03-29 2018-10-04 F. Hoffmann-La Roche Ag Bispecific antigen binding molecule for a costimulatory tnf receptor
EP3601346A1 (en) 2017-03-29 2020-02-05 H. Hoffnabb-La Roche Ag Bispecific antigen binding molecule for a costimulatory tnf receptor
WO2018184965A1 (en) 2017-04-03 2018-10-11 F. Hoffmann-La Roche Ag Immunoconjugates of il-2 with an anti-pd-1 and tim-3 bispecific antibody
KR102667951B1 (ko) 2017-04-03 2024-05-22 에프. 호프만-라 로슈 아게 Steap-1에 결합하는 항체
LT3606946T (lt) 2017-04-03 2022-10-25 F. Hoffmann-La Roche Ag Anti-pd-1 antikūno imunokonjugatai su mutantiniu il-2 arba su il-15
AU2018247796A1 (en) 2017-04-04 2019-08-29 F. Hoffmann-La Roche Ag Novel bispecific antigen binding molecules capable of specific binding to CD40 and to FAP
KR102346336B1 (ko) 2017-04-05 2022-01-04 에프. 호프만-라 로슈 아게 Pd1 및 lag3에 특이적으로 결합하는 이중특이적 항체
IL268620B2 (en) 2017-04-05 2024-04-01 Hoffmann La Roche Antibodies against LAG3 pharmaceutical formulations containing them, and their uses for cancer treatment
EP3615572A1 (en) 2017-04-27 2020-03-04 Tesaro Inc. Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
EP3625251A1 (en) 2017-05-15 2020-03-25 University Of Rochester Broadly neutralizing anti-influenza monoclonal antibody and uses thereof
WO2018213316A1 (en) 2017-05-16 2018-11-22 Alector Llc Anti-siglec-5 antibodies and methods of use thereof
WO2018226750A1 (en) 2017-06-06 2018-12-13 Relinia, Inc. Single-chain tnf receptor 2 agonist fusion proteins
EP3652211A1 (en) 2017-07-14 2020-05-20 Pfizer Inc. Antibodies to madcam
AU2018310985A1 (en) 2017-08-03 2019-11-07 Alector Llc Anti-CD33 antibodies and methods of use thereof
IL270235B2 (en) 2017-08-03 2025-02-01 Alector Llc Anti-TREM2 antibodies and methods of using them
WO2019033043A2 (en) 2017-08-11 2019-02-14 Genentech, Inc. ANTI-CD8 ANTIBODIES AND USES THEREOF
IL253984A0 (en) 2017-08-14 2017-09-28 Yeda Res & Dev Immunotherapy against aranviruses that bind through transferrin receptor 1 (tfr1
SG11202001551YA (en) 2017-08-21 2020-03-30 Adagene Inc Dynamic human heavy chain antibody libraries
JP7324744B2 (ja) 2017-08-21 2023-08-10 アダジーン インコーポレイテッド ダイナミックヒト抗体軽鎖ライブラリー
CN111511762B (zh) 2017-08-21 2025-05-06 天演药业公司 抗cd137分子及其用途
IL317013A (en) 2017-09-08 2025-01-01 Takeda Pharmaceuticals Co Binding proteins are activated under limited conditions
CN111315773A (zh) 2017-09-08 2020-06-19 马弗里克治疗公司 含有Fc区的条件性活化的结合部分
MY204641A (en) 2017-09-29 2024-09-06 Chugai Pharmaceutical Co Ltd Multispecific antigen-binding molecule having blood coagulation factor viii (fviii) cofactor function-substituting activity, and pharmaceutical formulation containing said molecule as active ingredient
EP3704145A1 (en) 2017-10-30 2020-09-09 F. Hoffmann-La Roche AG Method for in vivo generation of multispecific antibodies from monospecific antibodies
EP3704155A2 (en) 2017-11-01 2020-09-09 F. Hoffmann-La Roche AG Combination therapy with targeted ox40 agonists
SG11202002903XA (en) 2017-11-01 2020-04-29 Hoffmann La Roche Bispecific 2+1 contorsbodies
EP3704150A1 (en) 2017-11-01 2020-09-09 F. Hoffmann-La Roche AG The compbody - a multivalent target binder
JP2021500902A (ja) 2017-11-01 2021-01-14 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 新規ｔｎｆファミリーリガンド三量体含有抗原結合分子
JP7092881B2 (ja) 2017-11-01 2022-06-28 エフ．ホフマン－ラ ロシュ アーゲー ＴｒｉＦａｂコントースボディ
JP7731196B2 (ja) 2017-11-14 2025-08-29 中外製薬株式会社 抗Ｃ１ｓ抗体および使用方法
WO2019108755A1 (en) 2017-11-30 2019-06-06 Genentech, Inc. Anti-pd-l1 antibodies and methods of using the same for detection of pd-l1
AU2018390881A1 (en) 2017-12-21 2020-07-02 F. Hoffmann-La Roche Ag Antibodies binding to HLA-A2/WT1
EP3502140A1 (en) 2017-12-21 2019-06-26 F. Hoffmann-La Roche AG Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules
CN111511400B (zh) 2017-12-29 2025-08-29 豪夫迈·罗氏有限公司 抗vegf抗体及其使用方法
CN111886246B (zh) 2017-12-29 2024-12-17 艾莱克特有限责任公司 抗tmem106b抗体及其使用方法
SG11202006348VA (en) 2018-01-05 2020-07-29 Ac Immune Sa Misfolded tdp-43 binding molecules
WO2019139987A1 (en) 2018-01-09 2019-07-18 Elstar Therapeutics, Inc. Calreticulin binding constructs and engineered t cells for the treatment of diseases
EP3740505A1 (en) 2018-01-16 2020-11-25 Lakepharma Inc. Bispecific antibody that binds cd3 and another target
CN112020365A (zh) 2018-01-26 2020-12-01 豪夫迈·罗氏有限公司 组合物和使用方法
RU2020127792A (ru) 2018-01-26 2022-02-28 Дженентек, Инк. СЛИТЫЕ БЕЛКИ IL-22- Fc И СПОСОБЫ ПРИМЕНЕНИЯ
WO2019152715A1 (en) 2018-01-31 2019-08-08 Alector Llc Anti-ms4a4a antibodies and methods of use thereof
CN116041516A (zh) 2018-02-01 2023-05-02 信达生物制药(苏州)有限公司 全人源的抗b细胞成熟抗原(bcma)单链抗体及其应用
WO2019148445A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
WO2019148444A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Anti-ctla4 antibodies and methods of making and using the same
TWI829667B (zh) 2018-02-09 2024-01-21 瑞士商赫孚孟拉羅股份公司 結合gprc5d之抗體
EP3752530A1 (en) 2018-02-14 2020-12-23 ABBA Therapeutics AG Anti-human pd-l2 antibodies
EP3755364A1 (en) 2018-02-21 2020-12-30 F. Hoffmann-La Roche AG Dosing for treatment with il-22 fc fusion proteins
EP3755792A4 (en) 2018-02-23 2021-12-08 Pioneer Hi-Bred International, Inc. NEW CASE ORTHOLOGISTS9
MX2020008882A (es) 2018-02-26 2021-01-08 Genentech Inc Dosificación para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1.
EP3533460A1 (en) 2018-03-02 2019-09-04 Diaccurate Therapeutic anti-spla2-gib antibodies and the uses thereof
EP3533459A1 (en) 2018-03-02 2019-09-04 Diaccurate Anti-pla2-gib antibodies and the uses thereof
WO2019170677A1 (en) 2018-03-05 2019-09-12 Etablissement Francais Du Sang Recombinant single chain immunoglobulins
TWI841551B (zh) 2018-03-13 2024-05-11 瑞士商赫孚孟拉羅股份公司 使用靶向4-1bb (cd137)之促效劑的組合療法
ES2998140T3 (en) 2018-03-13 2025-02-19 Hoffmann La Roche Therapeutic combination of 4-1bb agonists with anti-cd20 antibodies
US20200040103A1 (en) 2018-03-14 2020-02-06 Genentech, Inc. Anti-klk5 antibodies and methods of use
EP3765517A1 (en) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
TWI827585B (zh) 2018-03-15 2024-01-01 日商中外製藥股份有限公司 對茲卡病毒具有交叉反應性的抗登革病毒抗體及其使用方法
WO2019183437A1 (en) 2018-03-23 2019-09-26 North Carolina State University Methods and compositions for antibody to high affinity receptor for ige
WO2019192432A1 (zh) 2018-04-02 2019-10-10 上海博威生物医药有限公司 结合淋巴细胞活化基因-3(lag-3)的抗体及其用途
TW202011029A (zh) 2018-04-04 2020-03-16 美商建南德克公司 偵測及定量fgf21之方法
AR114284A1 (es) 2018-04-13 2020-08-12 Hoffmann La Roche Moléculas de unión a antígeno dirigidas a her2 que comprenden 4-1bbl
AR114789A1 (es) 2018-04-18 2020-10-14 Hoffmann La Roche Anticuerpos anti-hla-g y uso de los mismos
AR115052A1 (es) 2018-04-18 2020-11-25 Hoffmann La Roche Anticuerpos multiespecíficos y utilización de los mismos
FR3080621B1 (fr) 2018-04-26 2022-12-09 Univ Limoges Nouvelle classe d'immunoglobuline recombinante de type g : igg5, codee par le pseudo-gene gamma humain de chaine lourde
EP3787678A1 (en) 2018-05-03 2021-03-10 University Of Rochester Anti-influenza neuraminidase monoclonal antibodies and uses thereof
BR112020023844A2 (pt) 2018-05-25 2021-04-13 Alector Llc Anticorpos, métodos de tratamento do câncer e de produção de um anticorpo, ácido nucleico, vetor, células hospedeiras e composição farmacêutica
EP3805400A4 (en) 2018-06-04 2022-06-29 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule showing changed half-life in cytoplasm
AU2019282778A1 (en) 2018-06-08 2020-12-10 Alector Llc Anti-Siglec-7 antibodies and methods of use thereof
MY205645A (en) 2018-06-23 2024-11-02 Genentech Inc Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
WO2020006374A2 (en) 2018-06-29 2020-01-02 Alector Llc Anti-sirp-beta1 antibodies and methods of use thereof
DE202019005887U1 (de) 2018-07-03 2023-06-14 Marengo Therapeutics, Inc. Anti-TCR-Antikörpermoleküle und Verwendungen davon
JP2021528988A (ja) 2018-07-04 2021-10-28 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 新規の二重特異性アゴニスト４−１ｂｂ抗原結合分子
MY202133A (en) 2018-07-13 2024-04-05 Alector Llc Anti-sortilin antibodies and methods of use thereof
CA3105222A1 (en) 2018-07-17 2020-01-23 Humabs Biomed Sa Antibodies against campylobacter species
BR112021000727A2 (pt) 2018-07-20 2021-04-13 Surface Oncology, Inc. Composições anti-cd112r e métodos
EP3830123A1 (en) 2018-07-27 2021-06-09 Alector LLC Anti-siglec-5 antibodies and methods of use thereof
US12435137B2 (en) 2018-08-03 2025-10-07 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule containing two antigen-binding domains that are linked to each other
MX2021001453A (es) 2018-08-08 2021-04-12 Genentech Inc Uso de derivados de triptofano y l-metionina para una formulacion de proteinas.
AU2019318031B2 (en) 2018-08-10 2025-06-05 Chugai Seiyaku Kabushiki Kaisha Anti-CD137 antigen-binding molecule and utilization thereof
TW202021618A (zh) 2018-08-17 2020-06-16 美商２３與我有限公司 抗ｉｌ１ｒａｐ抗體及其使用方法
BR112021003016A2 (pt) 2018-08-31 2021-05-18 Alector Llc anticorpos isolados, ácido nucleico isolado, vetor, célula hospedeira, métodos para produzir um anticorpo e para prevenir, reduzir o risco ou tratar uma doença e composição farmacêutica
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
EP3846840A4 (en) * 2018-09-05 2022-06-15 Ventria Bioscience Inc. Formulations of immunoglobulin a
JP7475336B2 (ja) 2018-09-21 2024-04-26 ジェネンテック， インコーポレイテッド トリプルネガティブ乳癌のための診断方法
UA126188C2 (uk) 2018-10-01 2022-08-25 Ф. Хоффманн-Ля Рош Аг Біспецифічна антигензв'язувальна молекула, яка містить домен зв'язування з fap та домен зв'язування з сd40
JP2022511396A (ja) 2018-10-01 2022-01-31 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｃｄ４０への三価結合を伴う二重特異性抗原結合分子
WO2020081493A1 (en) 2018-10-16 2020-04-23 Molecular Templates, Inc. Pd-l1 binding proteins
IL282441B2 (en) 2018-10-24 2025-07-01 Hoffmann La Roche Conjugated chemical inducers of degradation and methods of use
MX2021006573A (es) 2018-12-06 2021-07-15 Genentech Inc Tratamiento conjunto de linfoma difuso de linfocitos b grandes que comprende un inmunoconjugado anti-cd79b, un agente alquilante y un anticuerpo anti-cd20.
WO2020123275A1 (en) 2018-12-10 2020-06-18 Genentech, Inc. Photocrosslinking peptides for site specific conjugation to fc-containing proteins
AU2019398351A1 (en) 2018-12-14 2021-06-03 Pioneer Hi-Bred International, Inc. Novel CRISPR-Cas systems for genome editing
SG11202106483WA (en) 2018-12-19 2021-07-29 Humabs Biomed Sa Antibodies that neutralize hepatitis b virus and uses thereof
AR117327A1 (es) 2018-12-20 2021-07-28 23Andme Inc Anticuerpos anti-cd96 y métodos de uso de estos
WO2020132230A2 (en) 2018-12-20 2020-06-25 Genentech, Inc. Modified antibody fcs and methods of use
WO2020127628A1 (en) 2018-12-21 2020-06-25 F. Hoffmann-La Roche Ag Tumor-targeted superagonistic cd28 antigen binding molecules
WO2020127618A1 (en) 2018-12-21 2020-06-25 F. Hoffmann-La Roche Ag Tumor-targeted agonistic cd28 antigen binding molecules
PH12021551422A1 (en) 2018-12-21 2022-05-02 23Andme Inc Anti-il-36 antibodies and methods of use thereof
KR102720337B1 (ko) 2018-12-21 2024-10-24 에프. 호프만-라 로슈 아게 Cd3에 결합하는 항체
CN113272327A (zh) 2018-12-30 2021-08-17 豪夫迈·罗氏有限公司 抗兔cd19抗体及其使用方法
JP2022522985A (ja) 2019-01-22 2022-04-21 ジェネンテック， インコーポレイテッド 免疫グロブリンａ抗体、並びに産生及び使用の方法
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
AU2020226893B2 (en) 2019-02-21 2025-02-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to T cell related cancer cells and uses thereof
SG11202108955QA (en) 2019-02-21 2021-09-29 Marengo Therapeutics Inc Antibody molecules that bind to nkp30 and uses thereof
CN113710706A (zh) 2019-02-27 2021-11-26 豪夫迈·罗氏有限公司 用于抗tigit抗体和抗cd20抗体或抗cd38抗体治疗的给药
EP3934761A1 (en) 2019-03-05 2022-01-12 Takeda Pharmaceutical Company Limited Conditionally activated binding proteins containing fc regions and moieties targeting tumor antigens
JP2022524338A (ja) 2019-03-05 2022-05-02 武田薬品工業株式会社 拘束され、条件的に活性化された結合タンパク質
WO2020185535A1 (en) 2019-03-08 2020-09-17 Genentech, Inc. Methods for detecting and quantifying membrane-associated proteins on extracellular vesicles
WO2020189748A1 (ja) 2019-03-19 2020-09-24 中外製薬株式会社 Ｍｔａ依存的に抗原に対する結合活性が変化する抗原結合ドメインを含む抗原結合分子及び当該抗原結合ドメイン取得用ライブラリ
EP3952996A1 (en) 2019-04-12 2022-02-16 F. Hoffmann-La Roche AG Bispecific antigen binding molecules comprising lipocalin muteins
JP7593939B2 (ja) 2019-04-19 2024-12-03 ジェネンテック， インコーポレイテッド 抗ｍｅｒｔｋ抗体及びその使用方法
AU2020262309A1 (en) 2019-04-25 2021-10-14 F. Hoffmann-La Roche Ag Therapeutic multispecific polypeptides activated by polypeptide chain exchange
CA3132275A1 (en) 2019-04-25 2020-10-29 Ulrich Brinkmann Generation of antibody-derived polypeptides by polypeptide chain exchange
TW202106713A (zh) 2019-04-25 2021-02-16 瑞士商赫孚孟拉羅股份公司 具延長半衰期之可活化治療性多特異性多肽
JP7550794B2 (ja) 2019-05-14 2024-09-13 ジェネンテック， インコーポレイテッド 濾胞性リンパ腫を処置するための抗ｃｄ７９ｂ免疫複合体の使用方法
CN114008073B (zh) 2019-05-23 2025-08-12 Ac免疫有限公司 抗tdp-43结合分子及其用途
WO2020252066A1 (en) 2019-06-11 2020-12-17 Alector Llc Anti-sortilin antibodies for use in therapy
EP3990477A1 (en) 2019-06-26 2022-05-04 F. Hoffmann-La Roche AG Fusion of an antibody binding cea and 4-1bbl
CN114531878A (zh) 2019-06-27 2022-05-24 豪夫迈·罗氏有限公司 新颖icos抗体及包含它们的肿瘤靶向抗原结合分子
JP7511591B2 (ja) 2019-06-28 2024-07-05 エフ． ホフマン－ラ ロシュ アーゲー 抗体の製造方法
JP2022538139A (ja) 2019-07-02 2022-08-31 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 変異体インターロイキン－２及び抗ｃｄ８抗体を含む免疫複合体
MX2022000111A (es) 2019-07-10 2022-02-10 Chugai Pharmaceutical Co Ltd Moleculas de union a claudina-6 y usos de las mismas.
AR119382A1 (es) 2019-07-12 2021-12-15 Hoffmann La Roche Anticuerpos de pre-direccionamiento y métodos de uso
AR119393A1 (es) 2019-07-15 2021-12-15 Hoffmann La Roche Anticuerpos que se unen a nkg2d
WO2021018925A1 (en) 2019-07-31 2021-02-04 F. Hoffmann-La Roche Ag Antibodies binding to gprc5d
TWI874431B (zh) 2019-07-31 2025-03-01 美商阿列克特有限責任公司 抗ms4a4a抗體及其使用方法
CN119192386A (zh) 2019-07-31 2024-12-27 豪夫迈·罗氏有限公司 与gprc5d结合的抗体
EP4007773A1 (en) 2019-08-06 2022-06-08 Aprinoia Therapeutics Limited Antibodies that bind to pathological tau species and uses thereof
EP4013774A1 (en) 2019-08-13 2022-06-22 Elpis Biopharmaceuticals Engineered interleukin-2 receptor beta agonists
EP3786180A1 (en) 2019-08-27 2021-03-03 Diaccurate Antibodies and the uses thereof
WO2021042000A1 (en) 2019-08-29 2021-03-04 Vir Biotechnology, Inc. Antibody compositions and methods for treating hepatitis b virus infection
IL290752B1 (en) 2019-08-29 2025-10-01 Vir Biotechnology Inc Preparations and methods for treating influenza A infection
MX2022002738A (es) 2019-09-04 2022-06-27 Genentech Inc Agentes de union a cd8 y uso de los mismos.
WO2021050645A1 (en) 2019-09-12 2021-03-18 Genentech, Inc. Compositions and methods of treating lupus nephritis
WO2021055816A1 (en) 2019-09-18 2021-03-25 Molecular Templates, Inc. Pd-l1 binding molecules comprising shiga toxin a subunit scaffolds
AR119997A1 (es) 2019-09-18 2022-01-26 Genentech Inc Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecíficos anti-klk5 / klk7 y métodos de uso
EP4036116A4 (en) 2019-09-27 2024-01-24 Nanjing GenScript Biotech Co., Ltd. ANTI-VHH DOMAIN ANTIBODIES AND USE THEREOF
EP4048693A1 (en) 2019-09-27 2022-08-31 F. Hoffmann-La Roche AG Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
EP4034160A1 (en) 2019-09-27 2022-08-03 Janssen Biotech, Inc. Anti-ceacam antibodies and uses thereof
TW202122114A (zh) 2019-10-18 2021-06-16 美商建南德克公司 使用抗CD79b 免疫偶聯物治療彌漫性大B 細胞淋巴瘤的方法
CA3158893A1 (en) 2019-10-24 2021-04-29 Minotaur Therapeutics, Inc. Chimeric cytokine modified antibodies and methods of use thereof
AU2020378330A1 (en) 2019-11-06 2022-05-12 F. Hoffmann-La Roche Ag Diagnostic and therapeutic methods for treatment of hematologic cancers
MX2022005317A (es) 2019-11-15 2022-05-26 Hoffmann La Roche Prevencion de formacion de particulas visibles en soluciones acuosas de proteina.
EP4058479A4 (en) 2019-11-15 2024-02-28 University of Tennessee Research Foundation MODIFIED IMMUNOLOBULINES FOR TARGETING AMYLOID DEPOSITS
US20230028476A1 (en) 2019-12-03 2023-01-26 Evotec International Gmbh Interferon-associated antigen binding proteins for use in treating hepatitis b infection
WO2021110562A1 (en) 2019-12-03 2021-06-10 Evotec International Gmbh Interferon-associated antigen binding proteins and uses thereof
CA3081503A1 (en) 2019-12-06 2021-06-06 Zymeworks Inc. Methods of using a bispecific antigen-binding construct targeting her2 in combination with cdk4/6 inhibitors for the treatment of breast cancer
EP4073119A1 (en) 2019-12-12 2022-10-19 Alector LLC Methods of use of anti-cd33 antibodies
TW202136303A (zh) 2019-12-13 2021-10-01 美商阿列克特有限責任公司 抗mertk抗體及其使用方法
CR20220330A (es) 2019-12-13 2022-08-04 Genentech Inc Anticuerpos anti-ly6g6d y métodos de uso.
CR20220256A (es) 2019-12-18 2022-08-31 Hoffmann La Roche Anticuerpos que se unen a hla-a2/mage-a4
WO2021122733A1 (en) 2019-12-18 2021-06-24 F. Hoffmann-La Roche Ag Bispecific anti-ccl2 antibodies
CR20220334A (es) 2019-12-23 2022-08-26 Genentech Inc Anticuerpos específicos de apolipoproteína l1 y métodos de uso
MX2022007840A (es) 2019-12-27 2022-07-19 Chugai Pharmaceutical Co Ltd Anticuerpo anti antigeno-4 asociado al linfocito t citotoxico (ctla4) y uso del mismo.
CN116234829A (zh) 2020-01-03 2023-06-06 马伦戈治疗公司 抗tcr抗体分子及其用途
CA3162009A1 (en) 2020-01-09 2021-07-15 F. Hoffmann-La Roche Ag New 4-1bbl trimer-containing antigen binding molecules
CN110818795B (zh) 2020-01-10 2020-04-24 上海复宏汉霖生物技术股份有限公司 抗tigit抗体和使用方法
MX2022008773A (es) 2020-01-15 2022-10-03 Trutino Biosciences Inc Profármacos de citocinas il-2 que comprenden un enlazador escindible.
WO2022050954A1 (en) 2020-09-04 2022-03-10 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
WO2021194481A1 (en) 2020-03-24 2021-09-30 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
CN115768800A (zh) 2020-01-31 2023-03-07 克利夫兰诊所基金会 抗苗勒管激素受体2抗体和使用方法
BR112022015374A2 (pt) 2020-02-03 2022-10-11 Vir Biotechnology Inc Anticorpos contra sars-cov-2 e métodos de uso dos mesmos
JP7663883B2 (ja) 2020-02-10 2025-04-17 上海詩健生物科技有限公司 Ｃｌｄｎ１８．２抗体及びその使用
KR20220140786A (ko) 2020-02-10 2022-10-18 상하이 에스쿠겐 바이오테크놀로지 컴퍼니 리미티드 클라우딘18.2 항체 및 그것의 사용
TWI895351B (zh) 2020-02-12 2025-09-01 日商中外製藥股份有限公司 用於癌症之治療的抗cd137抗原結合分子
EP4245373A3 (en) 2020-02-26 2023-12-20 VIR Biotechnology, Inc. Antibodies against sars-cov-2
EP4114959A4 (en) * 2020-03-02 2024-04-03 ExpressTec LLC IMPROVED IMMUNOGLOBLIN EXPRESSION EFFICIENCY IN EUKARYOTES
AU2021236306A1 (en) 2020-03-13 2022-09-15 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
US11919948B2 (en) 2020-03-19 2024-03-05 Genentech, Inc. Isoform-selective anti-TGFβ antibodies and methods of use
CA3169967A1 (en) 2020-03-24 2021-09-30 Genentech, Inc. Tie2-binding agents and methods of use
JP7736688B2 (ja) 2020-03-31 2025-09-09 中外製薬株式会社 多重特異性抗原結合分子を製造するための方法
WO2021202590A1 (en) 2020-03-31 2021-10-07 Alector Llc Anti-mertk antibodies and methods of use thereof
US20230107644A1 (en) 2020-04-01 2023-04-06 University Of Rochester Monoclonal antibodies against the hemagglutinin (ha) and neuraminidase (na) of influenza h3n2 viruses
AR121706A1 (es) 2020-04-01 2022-06-29 Hoffmann La Roche Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap
WO2021201202A1 (ja) 2020-04-02 2021-10-07 中外製薬株式会社 多重特異性抗原結合分子を含む組成物における不純物分子の分析方法
WO2021203053A1 (en) 2020-04-03 2021-10-07 Vir Biotechnology, Inc. Immunotherapy targeting a conserved region in sars coronaviruses
WO2021207662A1 (en) 2020-04-10 2021-10-14 Genentech, Inc. Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome
US20240059757A1 (en) 2020-04-14 2024-02-22 Vir Biotechnology, Inc. Antibodies against sars-cov-2 and methods of using the same
JP2023521238A (ja) 2020-04-15 2023-05-23 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 免疫複合体
TW202206111A (zh) 2020-04-24 2022-02-16 美商建南德克公司 使用抗ｃｄ７９ｂ免疫結合物之方法
AU2021262744A1 (en) 2020-04-27 2022-10-06 The Regents Of The University Of California Isoform-independent antibodies to lipoprotein(a)
JP2023523480A (ja) 2020-04-28 2023-06-06 ザ ロックフェラー ユニバーシティー 中和抗ｓａｒｓ－ｃｏｖ－２抗体およびその使用方法
TW202204420A (zh) 2020-04-30 2022-02-01 美商建南德克公司 Ｋｒａｓ特異性抗體及其用途
TW202200212A (zh) 2020-05-03 2022-01-01 中國大陸商聯寧（蘇州）生物製藥有限公司 包含抗-trop-2抗體之抗體藥物結合物
BR112022022523A2 (pt) 2020-05-08 2023-01-10 Vir Biotechnology Inc Anticorpos contra sars-cov-2
BR112022022614A2 (pt) 2020-05-11 2023-02-07 Hoffmann La Roche Métodos para estimular uma resposta imune, melhorar uma imunoterapia, tratar uma doença, reduzir crescimento tumoral, produzir um imunoconjugado e produzir uma composição, método de vacinação, imunoconjugados, composição, usos e kits
WO2021228917A1 (en) 2020-05-15 2021-11-18 F. Hoffmann-La Roche Ag Prevention of visible particle formation in parenteral protein solutions
WO2021233853A1 (en) 2020-05-19 2021-11-25 F. Hoffmann-La Roche Ag The use of chelators for the prevention of visible particle formation in parenteral protein solutions
IL298668A (en) 2020-05-29 2023-01-01 23Andme Inc Antibodies against cd200r1 and methods of using them
WO2021247925A1 (en) 2020-06-03 2021-12-09 Vir Biotechnology, Inc. Structure-guided immunotherapy against sars-cov-2
AR122569A1 (es) 2020-06-08 2022-09-21 Hoffmann La Roche Anticuerpos anti-vhb y métodos de uso
AU2021288203A1 (en) 2020-06-12 2023-01-19 Vir Biotechnology, Inc. Antibody therapies for SARS-CoV-2 infection
MX2022015877A (es) 2020-06-16 2023-01-24 Genentech Inc Metodos y composiciones para tratar cancer de mama triple negativo.
US20210395366A1 (en) 2020-06-18 2021-12-23 Genentech, Inc. Treatment with anti-tigit antibodies and pd-1 axis binding antagonists
AU2021291407A1 (en) 2020-06-19 2022-09-29 F. Hoffmann-La Roche Ag Antibodies binding to CD3
WO2021255146A1 (en) 2020-06-19 2021-12-23 F. Hoffmann-La Roche Ag Antibodies binding to cd3 and cea
BR112022025856A2 (pt) 2020-06-19 2023-01-10 Hoffmann La Roche Anticorpo que se liga a cd3 e cd19, polinucleotídeo isolado, célula hospedeira, método de produção de um anticorpo que se liga a cd3 e cd19, composição farmacêutica, uso do anticorpo, método para tratar uma doença em um indivíduo e invenção
EP4168446A1 (en) 2020-06-19 2023-04-26 F. Hoffmann-La Roche AG Antibodies binding to cd3 and folr1
KR20230025783A (ko) 2020-06-19 2023-02-23 에프. 호프만-라 로슈 아게 면역 활성화 Fc 도메인 결합 분자
CN115698080A (zh) 2020-06-19 2023-02-03 豪夫迈·罗氏有限公司 蛋白酶活化的t细胞双特异性抗体
US20230235040A1 (en) 2020-06-22 2023-07-27 Almirall, S.A. Anti-il-36 antibodies and methods of use thereof
IL297880A (en) 2020-06-23 2023-01-01 Hoffmann La Roche Agonistic cd28 antigen binding molecules targeting her2
TW202208422A (zh) 2020-06-24 2022-03-01 美商維爾生物科技股份有限公司 經工程化之b型肝炎病毒中和抗體及其用途
WO2021260064A1 (en) 2020-06-25 2021-12-30 F. Hoffmann-La Roche Ag Anti-cd3/anti-cd28 bispecific antigen binding molecules
IT202000015754A1 (it) 2020-06-30 2021-12-30 Fond Toscana Life Sciences Antibodies to coronavirus
WO2022003530A1 (en) 2020-06-30 2022-01-06 Fondazione Toscana Life Sciences Neutralizing antibodies to sars coronavirus-2
JP2023532764A (ja) 2020-07-07 2023-07-31 エフ． ホフマン－ラ ロシュ アーゲー 治療用タンパク質製剤の安定剤としての代替界面活性剤
IL298921A (en) 2020-07-10 2023-02-01 Hoffmann La Roche Antibodies which bind to cancer cells and target radionuclides to said cells
PH12023550112A1 (en) 2020-07-17 2024-06-24 Genentech Inc Anti-notch2 antibodies and methods of use
IL299860A (en) 2020-07-21 2023-03-01 Genentech Inc Antibody-conjugated chemical factors for the discharge of BRM and their methods
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
AR123085A1 (es) 2020-07-31 2022-10-26 Genentech Inc FORMULACIONES DE ANTICUERPO ANTI-INTEGRINA b7 Y DISPOSITIVOS
MX2023001440A (es) 2020-08-07 2023-03-06 Genentech Inc Proteinas de fusion del ligando para flt3 y metodos de uso.
IL276627A (en) 2020-08-10 2022-03-01 Yeda Res & Dev Compositions for diagnosis and treatment of coronavirus infections
TW202221026A (zh) 2020-08-14 2022-06-01 瑞士商Ａｃ 免疫有限公司 人源化抗ｔｄｐ－４３結合分子及其用途
WO2022043517A2 (en) 2020-08-27 2022-03-03 Cureab Gmbh Anti-golph2 antibodies for macrophage and dendritic cell differentiation
WO2022044248A1 (ja) 2020-08-28 2022-03-03 中外製薬株式会社 ヘテロ二量体Ｆｃポリペプチド
IL301269A (en) 2020-09-14 2023-05-01 Ichnos Sciences S A Antibodies that bind to IL1RAP and their uses
IL301503A (en) 2020-09-23 2023-05-01 Yeda res & development co ltd Methods and compositions for treating coronaviral infections
WO2022066973A1 (en) 2020-09-24 2022-03-31 Fred Hutchinson Cancer Research Center Immunotherapy targeting pbk or oip5 antigens
CN116724053A (zh) 2020-09-24 2023-09-08 弗雷德哈钦森癌症中心 靶向sox2抗原的免疫治疗
JP2023545322A (ja) 2020-09-28 2023-10-27 ヴィア・バイオテクノロジー・インコーポレイテッド Ｓａｒｓ－ｃｏｖ－２に対する抗体
WO2022076462A1 (en) 2020-10-05 2022-04-14 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
EP4229093A1 (en) 2020-10-16 2023-08-23 Genentech, Inc. Anti-cleaved icaspase substrate antibodies and methods of use
CA3190782A1 (en) 2020-10-20 2022-04-28 F. Hoffmann-La Roche Ag Combination therapy of pd-1 axis binding antagonists and lrrk2 inhibitors
EP4232475A1 (en) 2020-10-20 2023-08-30 Kantonsspital St. Gallen Antibodies or antigen-binding fragments specifically binding to gremlin-1 and uses thereof
WO2022086957A1 (en) 2020-10-20 2022-04-28 Genentech, Inc. Peg-conjugated anti-mertk antibodies and methods of use
AU2021374594A1 (en) 2020-11-04 2023-06-01 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates
IL302400A (en) 2020-11-04 2023-06-01 Genentech Inc Subcutaneous dosing of bispecific anti-CD20/anti-CD3 antibodies
US11919945B2 (en) 2020-11-04 2024-03-05 The Rockefeller University Neutralizing anti-SARS-CoV-2 antibodies
TWI874719B (zh) 2020-11-04 2025-03-01 美商建南德克公司 用抗cd20/抗cd3雙特異性抗體進行治療之給藥
EP4244254A1 (en) 2020-11-16 2023-09-20 F. Hoffmann-La Roche AG Combination therapy with fap-targeted cd40 agonists
CA3199023A1 (en) 2020-11-23 2022-05-27 Davide Corti Broadly neutralizing antibodies against influenza neuraminidase
AU2021382620A1 (en) 2020-11-23 2023-06-15 Humabs Biomed Sa Antibodies against influenza a viruses
WO2022109317A1 (en) 2020-11-23 2022-05-27 Vir Biotechnology, Inc. Anti-influenza antibodies and combinations thereof
JP2023550785A (ja) 2020-11-25 2023-12-05 ヴィア・バイオテクノロジー・インコーポレイテッド 複数のベータコロナウイルスに結合する抗体
JP2023553399A (ja) 2020-12-02 2023-12-21 アレクトル エルエルシー 抗ソルチリン抗体の使用法
WO2022117692A2 (en) 2020-12-04 2022-06-09 F. Hoffmann-La Roche Ag Ph-dependent mutant interleukin-2 polypeptides
CN116917315A (zh) 2020-12-08 2023-10-20 维尔生物科技有限公司 用于治疗甲型流感感染的抗体和方法
CR20230263A (es) 2020-12-17 2023-08-21 Hoffmann La Roche Anticuerpos anti-hla-g y uso de estos
WO2022148732A1 (en) 2021-01-06 2022-07-14 F. Hoffmann-La Roche Ag Combination therapy employing a pd1-lag3 bispecific antibody and a cd20 t cell bispecific antibody
WO2022148853A1 (en) 2021-01-11 2022-07-14 F. Hoffmann-La Roche Ag Immunoconjugates
CA3206466A1 (en) 2021-01-12 2022-07-21 Christian Klein Split antibodies which bind to cancer cells and target radionuclides to said cells
US12060411B2 (en) 2021-01-15 2024-08-13 The Rockefeller University Neutralizing anti-SARS-CoV-2 antibodies
WO2022159842A1 (en) 2021-01-25 2022-07-28 Vir Biotechnology, Inc. Antibody combination therapies for sars-cov-2 infection
JP2024504167A (ja) 2021-01-26 2024-01-30 ヴィア・バイオテクノロジー・インコーポレイテッド Ｂ型肝炎ウイルス感染を処置するための抗体組成物および方法
WO2022162587A1 (en) 2021-01-27 2022-08-04 Centre Hospitalier Universitaire Vaudois (C.H.U.V.) Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
CA3206395A1 (en) 2021-01-28 2022-08-04 Hassan JUMAA-WEINACHT Method and means for modulating b-cell mediated immune responses
WO2022162203A1 (en) 2021-01-28 2022-08-04 Vaccinvent Gmbh Method and means for modulating b-cell mediated immune responses
CN117120084A (zh) 2021-01-28 2023-11-24 维肯芬特有限责任公司 用于调节b细胞介导的免疫应答的方法和手段
JP2024509695A (ja) 2021-02-03 2024-03-05 ジェネンテック， インコーポレイテッド 多重特異性結合タンパク質分解プラットフォームおよび使用方法
BR112023015652A2 (pt) 2021-02-04 2023-10-17 Genuv Inc Anticorpo ou fragmento de ligação a antígeno do mesmo que se liga a um epítopo de uma proteína de morte celular programada 1 (pd-1); molécula de ácido nucleico; vetor de clonagem ou de expressão; célula hospedeira; método para produzir o anticorpo ou fragmento de ligação a antígeno do mesmo; animal transgênico; molécula de ligação a antígeno multiespecífico, imunoconjugado, receptor de antígeno quimérico, receptor de célula t modificado ou vírus oncolítico; composição farmacêutica para prevenir ou tratar uma afecção associada a pd-1; método para prevenir ou tratar tumores, doenças autoimunes de câncer, doenças autoimunes, doenças neurológicas, doenças neurodegenerativas ou doenças infecciosas; composição farmacêutica para aumentar uma resposta imunológica em um indivíduo que tem câncer; e hibridoma
EP4291575A1 (en) 2021-02-09 2023-12-20 Humabs Biomed SA Antibodies against respiratory syncytial virus, human metapneumovirus and pneumonia virus of mice and methods of using the same
CA3210069A1 (en) 2021-03-03 2022-09-09 Tong Zhu Antibody-drug conjugates comprising an anti-bcma antibody
CN117062839A (zh) 2021-03-12 2023-11-14 基因泰克公司 抗klk7抗体、抗klk5抗体、多特异性抗klk5/klk7抗体和使用方法
TW202300521A (zh) 2021-03-15 2023-01-01 美商建南德克公司 治療狼瘡性腎炎的組成物及方法
US20220306700A1 (en) 2021-03-17 2022-09-29 Molecular Templates, Inc. Pd-l1 binding proteins comprising shiga toxin a subunit scaffolds and cd8+ t cell antigens
EP4308606A1 (en) 2021-03-18 2024-01-24 Alector LLC Anti-tmem106b antibodies and methods of use thereof
WO2022197877A1 (en) 2021-03-19 2022-09-22 Genentech, Inc. Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents
WO2022204202A1 (en) 2021-03-23 2022-09-29 Vir Biotechnology, Inc. Antibodies that bind to multiple sarbecoviruses
WO2022204274A1 (en) 2021-03-23 2022-09-29 Alector Llc Anti-tmem106b antibodies for treating and preventing coronavirus infections
EP4067376A1 (en) 2021-03-30 2022-10-05 Diaccurate Anti-pla2g1b monoclonal antibodies and uses thereof
EP4314032A1 (en) 2021-03-30 2024-02-07 F. Hoffmann-La Roche AG Protease-activated polypeptides
US20240301031A1 (en) 2021-03-31 2024-09-12 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Truncated taci polypeptide and fusion protein and use thereof
AR125344A1 (es) 2021-04-15 2023-07-05 Chugai Pharmaceutical Co Ltd Anticuerpo anti-c1s
CN118251420A (zh) 2021-04-28 2024-06-25 米诺陶治疗公司 人源化嵌合牛抗体和使用方法
CA3213632A1 (en) 2021-04-30 2022-11-03 F. Hoffmann-La Roche Ag Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
EP4334343A2 (en) 2021-05-06 2024-03-13 The Rockefeller University Neutralizing anti-sars- cov-2 antibodies and methods of use thereof
MX2023013264A (es) 2021-05-12 2023-11-30 Genentech Inc Metodos para usar inmunoconjugados anti-cd79b para tratar linfoma difuso de linfocitos b grandes.
JP2024518081A (ja) 2021-05-12 2024-04-24 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 Ｒａｎｋｌとｎｇｆに特異的に結合する抗原結合分子およびその医薬用途
WO2022237882A1 (zh) 2021-05-14 2022-11-17 江苏恒瑞医药股份有限公司 一种抗原结合分子
AU2022273303A1 (en) 2021-05-14 2023-11-02 Genentech, Inc. Agonists of trem2
CA3219124A1 (en) 2021-05-18 2022-11-24 University Of Tennessee Research Foundation Antibody-peptide fusion proteins for treating amyloid disorders
WO2022243261A1 (en) 2021-05-19 2022-11-24 F. Hoffmann-La Roche Ag Agonistic cd40 antigen binding molecules targeting cea
US20250296986A1 (en) 2021-05-24 2025-09-25 Vir Biotechnology, Inc. Engineered polypeptides
AR126009A1 (es) 2021-06-02 2023-08-30 Hoffmann La Roche Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam
TW202307006A (zh) 2021-06-03 2023-02-16 美商表面腫瘤學公司 用抗ｃｄ３９抗體及派姆單抗治療癌症之方法
WO2022255440A1 (en) 2021-06-04 2022-12-08 Chugai Seiyaku Kabushiki Kaisha Anti-ddr2 antibodies and uses thereof
MX2023014563A (es) 2021-06-09 2024-02-08 Hoffmann La Roche Combinacion de un inhibidor de braf particular (interruptor de paradoja) y un antagonista de union al eje de pd-1 para su uso en el tratamiento de cancer.
WO2022258720A1 (en) 2021-06-09 2022-12-15 Evotec International Gmbh Interferon-associated antigen binding proteins for use for the treatment or prevention of coronavirus infection
US20240279341A1 (en) 2021-06-16 2024-08-22 Alector Llc Bispecific anti-mertk and anti-pdl1 antibodies and methods of use thereof
EP4355783A1 (en) 2021-06-16 2024-04-24 Alector LLC Monovalent anti-mertk antibodies and methods of use thereof
WO2022263638A1 (en) 2021-06-17 2022-12-22 Centre Hospitalier Universitaire Vaudois (C.H.U.V.) Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
WO2022266659A1 (en) 2021-06-17 2022-12-22 Genentech, Inc. Anti-ubiquitination antibodies and methods of use
CA3221735A1 (en) 2021-06-18 2022-12-22 F. Hoffmann-La Roche Ag Bispecific anti-ccl2 antibodies
JP2024525188A (ja) 2021-06-18 2024-07-10 セリーニ バイオ インコーポレイテッド ヒトフィブリンまたはフィブリノゲンγＣドメインに結合する抗体および使用方法
WO2022270611A1 (ja) 2021-06-25 2022-12-29 中外製薬株式会社 抗ｃｔｌａ－４抗体
WO2022270612A1 (ja) 2021-06-25 2022-12-29 中外製薬株式会社 抗ｃｔｌａ－４抗体の使用
MX2024000611A (es) 2021-07-14 2024-02-02 Genentech Inc Anticuerpos anti-receptor de quimiocinas de motivo c-c 8 (ccr8) y metodos de uso.
MX2024000501A (es) 2021-07-14 2024-01-31 Jiangsu Hengrui Pharmaceuticals Co Ltd Molecula de union a antigeno que se une especificamente a hgfr y egfr, y su uso farmaceutico.
CN118556074A (zh) 2021-07-21 2024-08-27 特鲁提诺生物科学公司 接头多肽
CA3219606A1 (en) 2021-07-22 2023-01-26 F. Hoffmann-La Roche Ag Heterodimeric fc domain antibodies
EP4373576A1 (en) 2021-07-22 2024-05-29 Genentech, Inc. Brain targeting compositions and methods of use thereof
US20250215103A1 (en) 2021-08-03 2025-07-03 Hoffmann-La Roche Inc. Bispecific antibodies and methods of use
EP4388014A1 (en) 2021-08-19 2024-06-26 F. Hoffmann-La Roche AG Multivalent anti-variant fc-region antibodies and methods of use
TW202315895A (zh) 2021-08-27 2023-04-16 瑞士商休曼生物醫藥股份公司 經工程化的組成物
CA3228359A1 (en) 2021-08-27 2023-03-02 Genentech, Inc. Methods of treating tau pathologies
JP2024534853A (ja) 2021-08-30 2024-09-26 ジェネンテック， インコーポレイテッド 抗ポリビキチン多重特異性抗体
US20240400652A1 (en) 2021-09-01 2024-12-05 Vir Biotechnology, Inc. Antibody therapies for sars-cov-2 infection in pediatric subjects
WO2023034871A1 (en) 2021-09-01 2023-03-09 Vir Biotechnology, Inc. High concentration antibody therapies for sars-cov-2 infection
EP4399228A1 (en) 2021-09-07 2024-07-17 Etablissement Français du Sang Targeted regulation of platelet and megakaryocyte activation by heteroreceptor co-clustering
WO2023039442A1 (en) 2021-09-08 2023-03-16 Vir Biotechnology, Inc. Broadly neutralizing antibody combination therapies for sars-cov-2 infection
CA3232472A1 (en) 2021-09-23 2023-03-30 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anti-klb antibodies and uses
JPWO2023053282A1 (enExample) 2021-09-29 2023-04-06
EP4410841A4 (en) 2021-09-30 2025-08-13 Jiangsu Hengrui Pharmaceuticals Co Ltd ANTI-IL23 ANTIBODY FUSION PROTEIN AND USES THEREOF
WO2023056403A1 (en) 2021-09-30 2023-04-06 Genentech, Inc. Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists
EP4413998A1 (en) 2021-10-08 2024-08-14 Chugai Seiyaku Kabushiki Kaisha Method for preparing prefilled syringe formulation
CN118139648A (zh) 2021-10-14 2024-06-04 豪夫迈·罗氏有限公司 用于治疗癌症的替代的PD1-IL7v免疫缀合物
PE20241627A1 (es) 2021-10-14 2024-08-07 Hoffmann La Roche Nuevos inmunoconjugados de interleucina-7
WO2023069919A1 (en) 2021-10-19 2023-04-27 Alector Llc Anti-cd300lb antibodies and methods of use thereof
US20250251400A1 (en) 2021-11-05 2025-08-07 American Diagnostics & Therapy, Llc (Adxrx) Monoclonal Antibodies Against Carcinoembryonic Antigens, and Their Uses
WO2023081898A1 (en) 2021-11-08 2023-05-11 Alector Llc Soluble cd33 as a biomarker for anti-cd33 efficacy
JP2024544885A (ja) 2021-11-10 2024-12-05 ジェネンテック， インコーポレイテッド 抗インターロイキン－３３抗体及びその使用
IL312692A (en) 2021-11-16 2024-07-01 Genentech Inc Methods and compositions for the treatment of systemic lupus erythematosus (SLE) with musontuzumab
KR20240100369A (ko) 2021-11-16 2024-07-01 에이씨 이뮨 에스에이 치료 및 진단을 위한 신규한 분자
WO2023094980A1 (en) 2021-11-23 2023-06-01 Fondazione Toscana Life Sciences Antibodies to coronavirus
AR127887A1 (es) 2021-12-10 2024-03-06 Hoffmann La Roche Anticuerpos que se unen a cd3 y plap
KR20240122784A (ko) 2021-12-17 2024-08-13 상하이 헨리우스 바이오테크, 인크. 항-ox40 항체 및 사용 방법
CN118488965A (zh) 2021-12-17 2024-08-13 上海复宏汉霖生物技术股份有限公司 抗ox40抗体、多特异性抗体及其使用方法
CR20240246A (es) 2021-12-20 2024-07-19 Hoffmann La Roche Anticuerpos agonistas anti-ltbr y anticuerpos biespecificos que los comprenden
TW202340251A (zh) 2022-01-19 2023-10-16 美商建南德克公司 抗ｎｏｔｃｈ２抗體及結合物及其使用方法
US20250333485A1 (en) 2022-01-27 2025-10-30 The Rockefeller University Broadly neutralizing anti-sars-cov-2 antibodies targeting the n-terminal domain of the spike protein and methods of use thereof
CN118574855A (zh) 2022-02-07 2024-08-30 江苏恒瑞医药股份有限公司 特异性结合psma和cd3的抗原结合分子及其医药用途
AU2023221539A1 (en) 2022-02-16 2024-08-22 Ac Immune Sa Humanized anti-tdp-43 binding molecules and uses thereof
EP4495139A4 (en) 2022-03-14 2025-09-24 Jiangsu Hengrui Pharmaceuticals Co Ltd ANTIGEN-BINDING MOLECULE SPECIFICALLY BINDING TO GPRC5D AND CD3 AND ITS MEDICAL USE
IL314211A (en) 2022-03-23 2024-09-01 Genentech Inc Combined treatment of bispecific antibody and chemotherapy against CD20/ANTI-CD3
WO2023179740A1 (en) 2022-03-25 2023-09-28 Shanghai Henlius Biotech , Inc. Anti-msln antibodies and methods of use
JP2025511000A (ja) 2022-03-28 2025-04-15 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト インターフェロンガンマバリアントおよびこれを含む抗原結合分子
AR128876A1 (es) 2022-03-28 2024-06-19 Hoffmann La Roche Anticuerpos biespecíficos de linfocitos t activables con proteasa folr1 mejorados
JP2025512824A (ja) 2022-04-01 2025-04-22 ジェネンテック， インコーポレイテッド 抗ｆｃｒｈ５／抗ｃｄ３二重特異性抗体による処置のための投与
AU2023250038A1 (en) 2022-04-08 2024-11-14 Ac Immune Sa Anti-tdp-43 binding molecules
WO2023201256A1 (en) 2022-04-12 2023-10-19 Vir Biotechnology, Inc. High dose antibody therapies for sars-cov-2 infection
CA3255366A1 (en) 2022-04-13 2023-10-19 Hoffmann La Roche Pharmaceutical compositions based on bispecific anti-CD20/anti-CD3 antibodies and methods of use
CA3247428A1 (en) 2022-04-13 2023-10-19 Hoffmann La Roche Pharmaceutical compositions of therapeutic proteins and methods of use
WO2023201291A1 (en) 2022-04-13 2023-10-19 Genentech, Inc. Pharmaceutical compositions of mosunetuzumab and methods of use
WO2023203177A1 (en) 2022-04-20 2023-10-26 Kantonsspital St. Gallen Antibodies or antigen-binding fragments pan-specifically binding to gremlin-1 and gremlin-2 and uses thereof
EP4519322A1 (en) 2022-05-03 2025-03-12 Genentech, Inc. Anti-ly6e antibodies, immunoconjugates, and uses thereof
WO2023213969A1 (en) 2022-05-05 2023-11-09 Juno Therapeutics Gmbh Viral-binding protein and related reagents, articles, and methods of use
EP4522653A1 (en) 2022-05-11 2025-03-19 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
EP4529464A2 (en) 2022-05-23 2025-04-02 Humabs Biomed SA Broadly neutralizing antibodies against influenza neuraminidase
AR129399A1 (es) 2022-05-23 2024-08-21 Vir Biotechnology Inc Anticuerpos diseñados neutralizantes del virus de la hepatitis b y usos de los mismos
WO2023230448A1 (en) 2022-05-23 2023-11-30 Vir Biotechnology, Inc. Combination immunotherapy for influenza
AU2023284422A1 (en) 2022-06-07 2024-12-19 Genentech, Inc. Method for determining the efficacy of a lung cancer treatment comprising an anti-pd-l1 antagonist and an anti-tigit antagonist antibody
EP4536701A2 (en) 2022-06-08 2025-04-16 Institute for Research in Biomedicine (IRB) Cross-specific antibodies, uses and methods for discovery thereof
WO2023245078A1 (en) 2022-06-15 2023-12-21 Humabs Biomed Sa Anti-parvovirus antibodies and uses thereof
CN119256017A (zh) 2022-06-23 2025-01-03 江苏恒瑞医药股份有限公司 特异性结合dll3和cd3的抗原结合分子及其医药用途
WO2024006472A1 (en) 2022-06-30 2024-01-04 Vir Biotechnology, Inc. Antibodies that bind to multiple sarbecoviruses
AU2023305619A1 (en) 2022-07-13 2025-01-23 F. Hoffmann-La Roche Ag Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
JP2025523845A (ja) 2022-07-19 2025-07-25 ジェネンテック， インコーポレイテッド 抗ｆｃｒｈ５／抗ｃｄ３二重特異性抗体による処置のための投薬
MA71559A (fr) 2022-07-22 2025-05-30 Genentech, Inc. Molécules de liaison à l'antigène anti-steap1 et leurs utilisations
WO2024026411A1 (en) 2022-07-27 2024-02-01 Humabs Biomed Sa Broadly neutralizing antibodies against rsv and mpv paramyxoviruses
AU2023314795A1 (en) 2022-07-29 2025-03-06 Alector Llc Anti-gpnmb antibodies and methods of use thereof
JP2025525885A (ja) 2022-08-05 2025-08-07 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 Ｇｕｃｙ２ｃとｃｄ３に特異的に結合する抗原結合分子及びその医薬的使用
CN120077068A (zh) 2022-08-18 2025-05-30 英美偌科有限公司 多结构域结合分子
JP2025526897A (ja) 2022-08-18 2025-08-15 イムノコア リミテッド 複数ドメイン結合性分子
CN120076819A (zh) 2022-08-18 2025-05-30 英美偌科有限公司 多结构域结合分子
TW202417476A (zh) 2022-08-18 2024-05-01 英商英美偌科有限公司 Ｔ細胞受體及其融合蛋白
CA3265385A1 (en) 2022-08-22 2024-02-29 Abdera Therapeutics Inc DLL3 BINDING MOLECULES AND THEIR USES
CN119698435A (zh) 2022-09-08 2025-03-25 江苏恒瑞医药股份有限公司 抗ilt4抗体及其医药用途
EP4584297A1 (en) 2022-09-11 2025-07-16 Yeda Research and Development Co. Ltd Anti-klk4 antibodies and uses thereof
JP2025533570A (ja) 2022-09-28 2025-10-07 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 改良されたプロテアーゼ活性化型ｔ細胞二重特異性抗体
EP4594345A1 (en) 2022-09-29 2025-08-06 F. Hoffmann-La Roche AG Protease-activated polypeptides
WO2024068996A1 (en) 2022-09-30 2024-04-04 Centre Hospitalier Universitaire Vaudois (C.H.U.V.) Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
CN119998323A (zh) 2022-10-07 2025-05-13 基因泰克公司 使用抗c-c基序趋化因子受体8(ccr8)抗体治疗癌症的方法
WO2024079074A1 (en) 2022-10-10 2024-04-18 Universite D'aix Marseille ANTI-sCD146 ANTIBODIES AND USES THEREOF
WO2024086796A1 (en) 2022-10-20 2024-04-25 Alector Llc Anti-ms4a4a antibodies with amyloid-beta therapies
AU2023367741A1 (en) 2022-10-25 2025-05-01 Genentech, Inc. Therapeutic and diagnostic methods for multiple myeloma
TW202434286A (zh) 2022-11-08 2024-09-01 美商建南德克公司 治療兒童期發病的特發性腎病症候群之組成物及方法
WO2024100200A1 (en) 2022-11-09 2024-05-16 Cis Pharma Ag Anti-l1-cam antibodies and their uses for diagnostic and therapeutic applications
WO2024100170A1 (en) 2022-11-11 2024-05-16 F. Hoffmann-La Roche Ag Antibodies binding to hla-a*02/foxp3
WO2024104988A1 (en) 2022-11-15 2024-05-23 F. Hoffmann-La Roche Ag Recombinant binding proteins with activatable effector domain
CN120187748A (zh) 2022-11-15 2025-06-20 豪夫迈·罗氏有限公司 抗原结合分子
WO2024107749A1 (en) 2022-11-16 2024-05-23 Attralus, Inc. Fusion proteins that bind amyloid and the transferrin receptor and uses thereof
WO2024112818A1 (en) 2022-11-22 2024-05-30 Humabs Biomed Sa Engineered anti-sars-cov-2 antibodies and uses thereof
AR131163A1 (es) 2022-11-25 2025-02-19 Chugai Pharmaceutical Co Ltd Métodos para producir proteínas
WO2024118998A2 (en) 2022-12-01 2024-06-06 Vir Biotechnology, Inc. Engineered anti-sars-cov-2 antibodies and methods of using the same
EP4631974A1 (en) 2022-12-08 2025-10-15 Nanjing Vazyme Biotech Co., Ltd. Antibody specifically binding to rsv
WO2024126294A1 (en) 2022-12-13 2024-06-20 Evotec International Gmbh Interferon-associated antigen binding proteins for use for the treatment or prevention of parainfluenza virus infection
WO2024126293A1 (en) 2022-12-13 2024-06-20 Evotec International Gmbh Interferon-associated antigen binding proteins for use for the treatment or prevention of respiratory syncytial virus infection
WO2024126289A1 (en) 2022-12-13 2024-06-20 Evotec International Gmbh Interferon-associated antigen binding proteins for use for the treatment or prevention of influenza virus infection
CN120344665A (zh) 2022-12-27 2025-07-18 中外制药株式会社 具有受控缔合的多肽
WO2024148232A2 (en) 2023-01-06 2024-07-11 Alector Llc Anti-il18 binding protein antibodies and methods of use thereof
WO2024146951A1 (en) 2023-01-06 2024-07-11 Immunocore Limited Binding molecules against a prame peptide-hla complex
US12195534B2 (en) 2023-01-06 2025-01-14 Immunocore Limited Binding molecules
WO2024155807A1 (en) 2023-01-18 2024-07-25 Genentech, Inc. Multispecific antibodies and uses thereof
EP4651885A1 (en) 2023-01-20 2025-11-26 F. Hoffmann-La Roche AG Recombinant fc domain - il2 variant polypeptides and combination therapy with membrane-anchored antigen binding polypeptides
IT202300000924U1 (it) 2023-01-23 2024-12-22 Philomena Dove Cucitura all-up leggins seamless
CN120569410A (zh) 2023-01-25 2025-08-29 豪夫迈·罗氏有限公司 与csf1r和cd3结合的抗体
WO2024182781A1 (en) 2023-03-02 2024-09-06 Vir Biotechnology, Inc. Coronavirus compositions and uses thereof
CN120917043A (zh) 2023-03-08 2025-11-07 Ac免疫有限公司 抗tdp-43结合分子及其用途
WO2024191785A1 (en) 2023-03-10 2024-09-19 Genentech, Inc. Fusions with proteases and uses thereof
CN120835901A (zh) 2023-03-13 2025-10-24 豪夫迈·罗氏有限公司 采用pd1-lag3双特异性抗体和hla-g t细胞双特异性抗体的组合疗法
US20240327522A1 (en) 2023-03-31 2024-10-03 Genentech, Inc. Anti-alpha v beta 8 integrin antibodies and methods of use
AU2024255423A1 (en) 2023-04-10 2025-10-30 Vir Biotechnology, Inc. Antibodies that bind to multiple sarbecoviruses
WO2024213635A1 (en) 2023-04-12 2024-10-17 Evotec International Gmbh Interferon-associated antigen binding proteins for use for the treatment or prevention of hepatitis delta virus infection
WO2024213596A1 (en) 2023-04-13 2024-10-17 F. Hoffmann-La Roche Ag Improved recombinant polyadenylation signal sequences and use thereof
WO2024220546A2 (en) 2023-04-17 2024-10-24 Peak Bio, Inc. Antibodies and antibody-drug conjugates and methods of use and synthetic processes and intermediates
GB202306345D0 (en) 2023-04-28 2023-06-14 Immunocore Ltd Binding molecules
WO2024233341A1 (en) 2023-05-05 2024-11-14 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
AU2024269754A1 (en) 2023-05-08 2025-10-23 F. Hoffmann-La Roche Ag Targeted interferon alpha fusion proteins and methods of use
WO2024233646A1 (en) 2023-05-10 2024-11-14 Genentech, Inc. Methods and compositions for treating cancer
WO2024238537A1 (en) 2023-05-16 2024-11-21 F. Hoffmann-La Roche Ag Pd-1 -regulated il-2 immunocytokine and uses thereof
AU2024277829A1 (en) 2023-05-19 2025-12-04 Les Laboratoires Servier Anti-met antibodies, antibody-drug conjugates, compositions and uses thereof
TW202502811A (zh) 2023-06-01 2025-01-16 瑞士商赫孚孟拉羅股份公司 與ｂｃｍａ特異性結合之免疫刺激性抗原結合分子
WO2024246083A1 (en) 2023-06-01 2024-12-05 F. Hoffmann-La Roche Ag Bispecific antibodies targeting bcma and cd28
WO2024263845A1 (en) 2023-06-22 2024-12-26 Genentech, Inc. Treatment of multiple myeloma
TW202502809A (zh) 2023-06-22 2025-01-16 美商建南德克公司 抗體及其用途
WO2025010424A1 (en) 2023-07-06 2025-01-09 Vir Biotechnology, Inc. Antibodies against staphylococcus antigens and methods of using the same
WO2025015321A1 (en) 2023-07-13 2025-01-16 Vir Biotechnology, Inc. Broadly neutralizing antibodies against rsv and mpv paramyxoviruses
WO2025017153A1 (en) 2023-07-19 2025-01-23 F. Hoffmann-La Roche Ag Dsfv as an igg fragment format and methods of production and labelling thereof
IT202300015579A1 (it) 2023-07-25 2025-01-25 Fond Toscana Life Sciences Anticorpi contro covid-19 e altri coronavirus umani
WO2025021838A1 (en) 2023-07-26 2025-01-30 F. Hoffmann-La Roche Ag Antibodies binding to cd3
WO2025032070A1 (en) 2023-08-09 2025-02-13 F. Hoffmann-La Roche Ag Anti-a-beta protein antibodies, methods and uses thereof
WO2025032071A1 (en) 2023-08-09 2025-02-13 F. Hoffmann-La Roche Ag Mono and multispecific anti-trem2 antibodies, methods and uses thereof
WO2025032069A1 (en) 2023-08-09 2025-02-13 F. Hoffmann-La Roche Ag Mono and multispecific anti-trem2 antibodies, methods and uses thereof
WO2025046393A1 (en) 2023-08-25 2025-03-06 Fondazione Per L’Istituto Oncologico Di Ricerca (Ior) Reagents against human endogenous retroviruses to target cancer cells
AR133909A1 (es) 2023-09-25 2025-11-12 Hoffmann La Roche ANTICUERPO QUE SE UNE A C3bBb
AR133963A1 (es) 2023-09-29 2025-11-19 Trex Bio Inc MOLÉCULAS DE FUSIÓN VARIANTE TNF-a
WO2025094054A1 (en) 2023-11-01 2025-05-08 Immunocore Limited Method for purifying small multi-domain proteins
WO2025099120A1 (en) 2023-11-09 2025-05-15 F. Hoffmann-La Roche Ag Multispecific antibodies with conditional activity
WO2025106474A1 (en) 2023-11-14 2025-05-22 Genentech, Inc. Therapeutic and diagnostic methods for treating cancer with anti-fcrh5/anti-cd3 bispecific antibodies
WO2025117848A1 (en) 2023-12-01 2025-06-05 Genentech, Inc. Low-viscosity variants of antibodies
WO2025113643A1 (en) 2023-12-01 2025-06-05 Gilead Sciences Inc. Anti-fap-light fusion protein and use thereof
IT202300026115A1 (it) 2023-12-06 2025-06-06 Fond Per L’Istituto Oncologico Di Ricerca Ior Una strategia basata su anticorpi che mira ad erg oncogenico attivato nel cancro alla prostata
WO2025129010A1 (en) 2023-12-14 2025-06-19 Genentech, Inc. Methods of structure determination using antibodies
WO2025125386A1 (en) 2023-12-14 2025-06-19 F. Hoffmann-La Roche Ag Antibodies that bind to folr1 and methods of use
WO2025132503A1 (en) 2023-12-20 2025-06-26 F. Hoffmann-La Roche Ag Antibodies binding to ceacam5
WO2025133042A2 (en) 2023-12-22 2025-06-26 F. Hoffmann-La Roche Ag Activatable fusion proteins and methods of use
WO2025146662A1 (en) 2024-01-05 2025-07-10 Immunocore Limited Cd1a-pd-1 bispecific agonist for the treatment of atopic dermatitis
US20250249093A1 (en) 2024-02-01 2025-08-07 Astrazeneca Ab Cytokine engagers and uses thereof
WO2025176614A1 (en) 2024-02-20 2025-08-28 F. Hoffmann-La Roche Ag Novel pre-targeting antibodies and uses thereof
WO2025181189A1 (en) 2024-03-01 2025-09-04 F. Hoffmann-La Roche Ag Antibodies binding to cd3
WO2025202147A1 (en) 2024-03-27 2025-10-02 F. Hoffmann-La Roche Ag Interleukin-7 immunoconjugates
NL2037390B1 (en) 2024-04-03 2025-10-13 Academisch Ziekenhuis Leiden Selection and characterization of a peptide-based complement activator
US20250326833A1 (en) 2024-04-23 2025-10-23 Attovia Therapeutics, Inc. Il31-binding polypeptides and uses thereof
WO2025226808A1 (en) 2024-04-24 2025-10-30 Genentech, Inc. Compositions and methods of treating lupus nephritis
WO2025233867A1 (en) 2024-05-10 2025-11-13 Adaptam Therapeutics, S.L. Anti-siglec-9 antibodies and uses thereof
WO2025237931A1 (en) 2024-05-15 2025-11-20 F. Hoffmann-La Roche Ag Recombinant binding proteins with conditionally activatable t cell and nk cell recruiting effector domains
WO2025238187A1 (en) 2024-05-15 2025-11-20 Cis Biopharma Ag Immunoconjugates targeting l1-cam

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4762785A (en) * 1982-08-12 1988-08-09 Calgene, Inc. Novel method and compositions for introducting alien DNA in vivo
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4771002A (en) * 1984-02-24 1988-09-13 Lubrizol Genetics, Inc. Transcription in plants and bacteria
US4956282A (en) * 1985-07-29 1990-09-11 Calgene, Inc. Mammalian peptide expression in plant cells
IL85035A0 (en) * 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5202422A (en) * 1989-10-27 1993-04-13 The Scripps Research Institute Compositions containing plant-produced glycopolypeptide multimers, multimeric proteins and method of their use
JPH11504901A (ja) * 1994-12-30 1999-05-11 プラネット・バイオテクノロジー・インコーポレイテッド 植物における防御タンパク質を含む免疫グロブリンの製造法およびその使用

Also Published As

Publication number Publication date
US5959177A (en) 1999-09-28
EP0946717A4 (enExample) 1999-11-17
WO1997042313A1 (en) 1997-11-13
AU2932397A (en) 1997-11-26
CA2253454A1 (en) 1997-11-13
JP2000510340A (ja) 2000-08-15
US6417429B1 (en) 2002-07-09
EP0946717A1 (en) 1999-10-06

Similar Documents

Publication Publication Date Title
AU731137B2 (en) Transgenic plants expressing assembled secretory antibodies
EP1048734B1 (en) Method for producing plants containing glycopolypeptide multimers, eg immunoglobulins
US7005560B1 (en) Transgenic plants expressing assembled secretory antibodies
AU722668B2 (en) Methods for producing immunoglobulins containing protection proteins in plants and their use
JP2008194054A (ja) 植物における防御タンパク質を含む免疫グロブリンの製造法およびその使用
US7211389B2 (en) Method for producing immunoglobulins containing protection proteins and their use
US20050241023A1 (en) Transgenic plants expressing assembled secretory antibodies
US7037722B1 (en) Transgenic plants expressing assembled secretory antibodies
US6995014B1 (en) Transgenic plants expressing assembled secretory antibodies
AU5400101A (en) Trangenic plants expressing assembled secretory antibodies
AU773602B2 (en) Methods for producing immunoglobulins containing protection proteins in plants and their use
AU2004201094A1 (en) Methods for Producing Immunoglobulins Containing Protection Proteins in Plants and Their Use
HK1115390A (en) Methods for producing immunoglobulins containing protection proteins in plants and their use

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)